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SOMMARIO 
Le malattie genetiche da prioni sono malattie neurodegenerative molto rare ed inesorabilmente 
fatali causate da mutazioni nel gene PRNP, che codifica per la proteina prionica. Queste mutazioni 
favoriscono la conversione conformazionale della proteina nativa in un’isoforma patologica che si 
accumula nel sistema nervoso centrale degli individui affetti, causando neurodegenerazione 
tramite meccanismi ancora sconosciuti. 
Esistono numerose indicazioni che la morte neuronale in queste malattie sia preceduta, e 
probabilmente provocata, da disfunzioni sinaptiche, ma non è ancora stato trovato un nesso 
convincente tra questi due fenomeni. 
Il nostro gruppo ha recentemente dimostrato che una forma mutata della proteina prionica viene 
trattenuta all’interno della cellula nel reticolo endoplasmico, dove interagisce con la subunità α2-
δ1 dei canali del calcio voltaggio-dipendenti. Questa interazione, associata alla ritenzione 
intracellulare della proteina mutata, ostacola il corretto inserimento in membrana dei canali del 
calcio, inficiando il processo di neurotrasmissione. Questo fenomeno, però, ancora non identifica 
le cause della morte neuronale.  
D’altra parte è noto che la proteina prionica interagisce anche con altre proteine importanti per la 
funzionalità sinaptica, come ad esempio i recettori del glutammato. In questo studio abbiamo 
quindi voluto verificare se la ritenzione la proteina mutata potesse ostacolare anche il trasporto di 
questi recettori, con effetti deleteri sulla neurotrasmissione postsinaptica e sulla sopravvivenza 
neuronale. 
I nostri risultati, in effetti, dimostrano che la proteina prionica mutata impedisce l’inserimento in 
membrana dei recettori AMPA e NMDA, causando alterazioni strutturali e funzionali del 
compartimento postsinaptico e della trasmissione eccitatoria di base. Inoltre, la ritenzione 
intracellulare della subunità GluA2 dei recettori AMPA fa in modo che vengano esposti in 
membrana recettori privi di tale subunità e quindi permeabili al calcio, provocando un aumento 
della permeabilità neuronale a tale ione e, di conseguenza, un aumento della suscettibilità al 
danno eccitotossico. E’ interessante notare come proteine con mutazioni diverse interagiscono in 
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maniera differente con i recettori glutammatergici, ed abbiano quindi effetti specifici sulla 
localizzazione e sulla funzione di queste molecole. 
I risultati di questo studio descrivono un nuovo meccanismo patologico alla base delle malattie 
genetiche da prioni che potrebbe portare all’individuazione di interessanti strategie terapeutiche 
per queste condizioni ad oggi incurabili. 
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ABSTRACT 
Genetic prion diseases are rare, invariably fatal neurodegenerative disorders linked to mutations 
in the PRNP gene encoding the prion protein (PrP). PRNP mutations favor the conformational 
conversion of PrP into a pathogenic, misfolded isoform that accumulates in the central nervous 
system of affected individuals and kills neurons through an unknown mechanism. 
Evidence is emerging that neuronal loss in inherited prion diseases is preceded and possibly 
caused by synaptic dysfunctions. However, the ultimate link between synaptic dysfunction and 
neurodegeneration is yet to be found. 
We previously demonstrated that mutant PrP is retained in the endoplasmic reticulum where it 
interacts with the α2-δ1 subunit of voltage-gated calcium channels. This impairs the correct 
delivery of the channel complex to the cell surface, impacting synaptic transmission. Nevertheless, 
this phenomenon alone does not account for neurodegeneration. It has been shown that PrPC 
engages functional interactions with other proteins that are important for synaptic function, such 
as glutamate receptors. Here, we aimed to explore whether intracellular retention of mutant PrP 
affected also the trafficking of glutamate receptors, thereby producing adverse effects on 
neuronal function and survival. 
We found that mutant PrP impairs the membrane delivery of specific AMPA and NMDA receptor 
subunits, resulting in postsynaptic structural alterations and impaired basal glutamatergic 
transmission and synaptic plasticity. Moreover, retention of the GluA2 subunit of AMPA receptor 
results in exposure of GluA2-lacking, calcium-permeable AMPA receptors, leading to increased 
calcium permeability and enhanced sensitivity to excitotoxic cell death. Interestingly, distinct PrP 
mutations interact differently with glutamate receptors, altering their localization and function in 
different ways. 
Our findings identify a new pathological mechanism for genetic prion diseases and may lead to 
novel therapeutic approaches for such incurable conditions.  
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INTRODUCTION 
1. PRION DISEASES 
 
Prion diseases are a group of rare neurodegenerative disorders of humans and mammals, rapidly 
progressive and invariably fatal.  
They are often defined as Transmissible Spongiform Encephalopathies (TSE), since they are 
characterized by a spongiform degeneration of the Central Nervous System (CNS) and, in most 
cases, by infectivity which can occur both experimentally and naturally. Common histopathological 
features are vacuolation of the gray matter, neuronal loss, reactive astrogliosis and deposition of a 
misfolded, partially protease resistant form of an endogenous protein, the cellular prion protein 
(PrPC). 
Although the precise pathogenesis has not been completely elucidated yet, it is recognized that 
the abnormal isoform of the PrPC, called scrapie prion protein (PrPSc), has a central role. The 
presence of PrPSc in the nervous tissue of affected individuals is very often observed, and it is also 
necessary for infectivity. As it was extensively demonstrated, the key etiological event in such 
diseases is indeed the conversion of PrPC into PrPSc. 
 
Figure 1- Neuropathological changes in Creutzfeld-Jakob disease (CJD). (A) Spongiform change in the frontal cortex in sporadic 
CJD. (B) Cerebral PrPSc accumulation in sporadic CJD. (C) Thalamic gliosis in variant CJD (from Knight and Will, 2004). 
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1.1 HUMAN PRION DISEASES 
 
Human TSE can be sporadic, genetically inherited or acquired through infection. 
Sporadic diseases 
Approximately 85% of human prion diseases are sporadic forms of Creutzfeld-Jakob Disease (sCJD) 
(Aguzzi, Sigurdson et al. 2008). sCJD incidence is about one person per million per year, and it 
occurs in the absence of any evident exposure to people or animals infected with TSE or mutations 
in the PrP gene (PRNP), although a polymorphism at the codon 129 seems to be involved in the 
susceptibility. At codon 129 of PRNP, an individual may encode for methionine (M) or valine (V). In 
the normal UK population, the allelic distributions are approximately: MM 40%, VV 10%, MV 50%, 
whereas in sCJD cases they are: MM 68%, VV 16%, MV 16%. MM homozygosity is therefore a risk 
factor (Knight and Will 2004). 
The disease typically presents with a rapidly progressive dementia and myoclonus; cerebellar 
ataxia, visual symptoms, pyramidal and extrapyramidal signs, as well as characteristic 
electroencephalographic alterations can be present, and the progression usually culminates in a 
terminal akinetic mute state (Knight and Will 2004; Aguzzi, Sigurdson et al. 2008). Onset normally 
occurs between 45 and 75 years of age, with peak onset between 60 and 65 years. The clinical 
progression is very rapid, with death occurring often in 2–3 months. Around 70% of patients dies 
within 6 months (Collinge 2001). 
Genetic diseases 
Familial CJD (fCJD), Gertsmann-Sträussler-Scheinker (GSS) syndrome and Fatal Familial Insomnia  
are the most common inherited prion diseases (FFI). They depend on dominant, highly penetrant 
mutations in PRNP and represent the 10-15% of human TSEs. 
Hitherto, several point mutations or insertions have been described. Insertions occur in a region 
encoding four octapeptides and one nonapeptide and consist in octapeptide repeat expansions, 
the size of which affects the clinical phenotype (Knight and Will 2004). Although each mutation is 
normally associated to a specific disease, other genetic factors may influence the clinical 
phenotype. Among these, once again, the polymorphism at codon 129 has remarkable effects. For 
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example, the D178N mutation gives rise to fCJD when associated to 129V, and to FFI when 
associated to 129M. 
In most cases, the mutations are thought to favor the protein’s propensity to convert to PrPSc. 
However, there is now considerable evidence that different mutations may have different 
consequences besides prion generation, including the alteration of the cellular trafficking and 
localization of the protein (Wadsworth, Asante et al. 2010). 
The overall most common mutation is E200K, which is associated to fCJD. The clinical phenotype is 
similar to that of sCJD, but with a lower age of onset and a shorter duration. Disease clusters are 
present in Israel, Slovakia and Chile (Knight and Will 2004).  
FFI is characterized by sleep disturbances as well as vegetative and focal neurological signs as a 
result of thalamic lesions (Aguzzi, Sigurdson et al. 2008). It is caused by D178N/129M mutation 
and affects about 30 families worldwide. 
GSS syndrome is associated to other point mutations (the most common at codons 102 and 198), 
and is characterized by chronic progressive ataxia, terminal dementia and a long clinical duration 
from 2 to 10 years (Aguzzi, Sigurdson et al. 2008). 
 
 
Figure 2- Sequence variability in human PrP. Main mutations, polymorphisms, insertions and deletions that have been found in the 
human PrP gene. The positions of the mutations (listed above the protein) and polymorphisms (listed below the protein) are 
indicated. The asterisk indicates a stop codon and therefore this mutation results in a truncated protein (from Manson and Tuzi, 
2001). 
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Acquired diseases 
Transmissibility is one of the crucial traits of prion diseases (Aguzzi, Sigurdson et al. 2008). 
Although the definition refers to experimental transmission in animals through inoculation of 
infected brains extracts, many well documented cases of animal and human diseases acquired 
through infection do exist.  
Kuru is surely one of the most famous examples. It is a slowly progressive neurodegenerative 
disease that reached epidemic proportions within a population of Papua New Guinea between the 
beginning and the half of the 20th century. It propagated especially in women and children in 
consequence of oral exposure to infected nervous tissue occurring during cannibalistic rituals. 
Another example is iatrogenic CJD. Over the past 30 years about 300 cases of CJD have been 
caused by the transmission of infection from person to person during medical or surgical 
treatments (Knight and Will 2004), owing to the use of improperly sterilized neurosurgical 
instruments or in consequence of infected dura mater and corneal transplants or pituitary-derived 
growth hormone administration. Interestingly, cases arising from intracerebral or optic inoculation 
manifest clinically as classical CJD, with a rapidly progressive dementia, whereas those resulting 
from peripheral inoculation frequently present with a slowly progressive cerebellar ataxia, 
reminiscent of kuru. The incubation periods range from months in case of intracerebral exposure 
(19–46 months for dura mater grafts) to as many as 40 years (with an average of approximately 12 
years) after peripheral exposure (Collinge 2001). 
However, the most famous acquired human prion disease is certainly variant CJD (vCJD). This 
variant has been described for the first time in 1996 in some cases of CJD with atypical 
presentation. Compared to the classical form, vCJD primarily affects young adults, with a mean age 
of onset of 29 years and a longer duration, on average 14 months. It initially presents as a 
neuropsychiatric disorder with pronounced behavioral signs and sensory phenomena. Ataxia, 
dementia and involuntary movements progressively follow. CJD’s typical electroencephalographic 
alterations are absent and neuropathological features are different. Interestingly, vCJD is the sole 
human prion disease in which PrPSc depositions are detectable in tonsils and other lymphoreticular 
tissues in preclinical disease. Although no mutations in the PRNP gene were detected, all primary 
vCJD cases so far were found to carry the MM genotype at codon 129. 
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The initial occurrence of these patients in the UK some years after a Bovine Spongiform 
Encephalopathy (BSE) epidemic, indicated a possible association between the diseases. 
Subsequent studies showed indeed a great similarity in terms of neuropathological lesion 
distributions in mice, PrPSc glycoform gel banding patterns and neuropathology after transmission 
to monkeys. On these basis, vCJD is now thought to represent a spread of BSE from cattle to 
humans (Aguzzi, Sigurdson et al. 2008). 
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Figure 3- Epidemiology of CJD. (A) Age at death and (B) duration of the disease (months) in variant and sporadic CJD in the UK 
(from Knight and Will, 2004). 
 
Although there have been serious concerns about the possible epidemic proportions that vCJD 
could reach, only approximately 200 cases have been reported to date, and the incidence of the 
disease is now decreasing. It should be kept in mind, however, that other types of prion diseases, 
such as Chronic Wasting Disease of deer, are easily transmissible, and that horizontal spread of 
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prions can be mediated by body fluids such as saliva, milk and urine. Moreover, since millions of 
Europeans were most likely exposed to BSE, it is possible that some individuals might be 
asymptomatic carriers able to transmit the infection, for instance, via blood transfusion, as there is 
evidence that such a route of transmission of vCJD may have occurred 
(http://www.who.int/mediacentre/factsheets/fs180/en/). 
To date, validated diagnostic tests in living animals or humans and proven treatments for prion 
diseases are not available. For these reasons, prion diseases represent an issue of great 
importance for public health, requiring a strict adherence to guidelines for surveillance and 
prevention, and further extensive studies for a better understanding of such a peculiar 
phenomenon, and for the development of effective diagnosis and therapy. 
 
1.2 THE PROTEIN-ONLY HYPOTHESIS 
 
The unusual characteristics of TSEs have challenged some of the most established dogmas in life 
sciences, leading to one of the most debated theories in biology: the protein-only hypothesis. 
The first evidence of the peculiar nature of TSEs emerged in 1937 when sheep scrapie was 
transmitted through a vaccine prepared from sheep brains treated with formalin, which normally 
abolished any known form of infectivity. Later on, the infectious nature of other animal and 
human TSEs was confirmed in both naturally-occurring and experimental cases of transmission. 
Because of the long incubation period, the agent responsible for the diseases was initially thought 
to be a slow virus, but this hypothesis was soon called into question. The unknown agent, in fact, 
appeared to be extremely resistant to treatments that normally destroy nucleic acids, such as UV 
and ionizing radiations. Moreover, the minimum molecular weight necessary for infectivity was 
found to be of about 200 kDa, lower than the mass of any known virus. Eventually, although 
certain scientists remain skeptical about the “protein-only hypothesis”, in 30 years of 
investigations no conventional pathogen convincingly associated to TSEs was ever found. 
On the basis of these findings, a revolutionary hypothesis was formulated in 1967 by J.S.Griffith: 
the agent responsible for TSE transmission might be a protein endowed with the unprecedented 
ability to replicate in the body. The term “prion” was subsequently coined by S. Prusiner in 1982 to 
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define this new proteinaceous infectious particle. 
The first support to the theory came with the isolation of a specific protein, called prion protein 
(PrP), from infectious material. This protein was associated to infectivity, and infectivity was 
reducible by proteolytic treatments, although PrP showed to be rather protease-resistant. 
Purification of the protein permitted then to identify the endogenous PrP encoding gene, which 
was present also in the uninfected individuals and particularly expressed in the brain. Further 
studies associated all the familial TSEs to mutations in the same gene. 
Later, it became clear that PrP can exist in two isoforms: the normal PrPC and the pathological 
PrPSc.  The two versions differ in terms of chemical and physical properties, and PrPSc possesses 
one unique characteristic: the ability to self-propagate by converting the cellular isoform into the 
aberrant one. 
However, one of the biggest challenges for this theory has been to explain the existence of 
different prion strains. Prion strains are defined as infectious isolates that confer a specific 
phenotype, different from that of other isolates, when experimentally transmitted. In other words, 
individuals affected by prion diseases may develop different pathologies, the clinical, 
neuropathological and biochemical characteristics of which are maintained through serial 
transmission to rodents. In analogy to other infectious agents, these variants have been termed 
strains. A classical definition of strain refers to a genetic variant or subtype of the infectious agent 
responsible for the disease, but this concept, valid in virology, cannot be extended to prions, 
because the phenomenon is independent of nucleic acid sequence variations (Morales, Abid et al. 
2007). 
Prion strains differ in terms of incubation periods, clinical signs, distribution of brain lesions, tissue 
tropism and host range. For instance, when FFI prions are inoculated into mice, PrPSc deposition is 
confined to the thalamus, as occurs in the parental disease. In contrast, inoculation of fCJD prions 
produces a widespread deposition of PrPSc within the cortex and the deep nuclei (Prusiner 1998).  
To conciliate the strain phenomenon with the hypothesis of a protein-only infectious agent with 
no variations in its primary structure, it has been proposed that prion strains arise from 
conformational variability, that is, PrP can assume several different, self-propagating 
conformations, each encoding a distinct prion strain (Colby and Prusiner 2011). 
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As a matter of fact, it is well known that proteins may exist in different conformers with different 
functions (Prusiner 1998). Under this respect, it should not be surprising that a single protein may 
show so many different behaviors within the network of genetic, cellular and environmental 
combinations that characterize every single individual or system. 
Although difficult to accept, the prion hypothesis has resisted to all the attempts to disprove it, 
and recent reports demonstrating the generation of highly infectious prions completely in vitro 
have provided the ultimate proof for the protein-only hypothesis to be true (Diaz-Espinoza and 
Soto 2010).
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2. THE PRION PROTEIN 
 
PrP is encoded by an autosomal gene, PRNP, that in humans is located on the short arm of 
chromosome 20 (position 20p13). The gene contains two or three exons depending on the species, 
but the open reading frame (ORF) is entirely contained in one. Although some inter- and 
intraspecies variability exists, the sequence is highly conserved (Colby and Prusiner 2011). 
 
            Figure 
4- Murine PrP Gene. The murine PrP gene possesses three exons; exon 3 contains the whole open reading frame (ORF) and 3' 
untranslated region (3' UTR). Conversely, the human PrP gene (not shown) possesses two known and one putative exon; the 
equivalent of murine exon 2 has not been found in human RNA transcripts to date (from Manson and Tuzi, 2001). 
 
The protein is present in mammals and in other classes as marsupials, birds, reptiles and fish, and 
may be present in all the vertebrates (Collinge 2001; La Mendola, Pietropaolo et al. 2008). It is 
expressed since the first phases of embryogenesis and is found in many adult tissues, showing the 
highest expression levels in the CNS (Collinge 2001). Here, it is present in both astrocytes and 
neurons, where is particularly enriched in the synaptic membranes (Aguzzi, Sigurdson et al. 2008). 
Human PrP is translated as a 253 amino acids peptide. During the maturation process, PrP 
undergoes the cleavage of a 22 amino acid, amino-terminal (N-terminal) signal, and a 23 amino 
acid carboxy-terminal (C-terminal) peptide which drives the addition of a 
glycosylphosphatidylinositol (GPI) anchor (Colby and Prusiner 2011). The mature protein has an 
unstructured N-terminal domain of about 100 amino acids and a globular C-terminal domain. This 
contains 3 α-helices and a two-stranded antiparallel β-sheet, and it is stabilized by a disulphide 
bond between helices 2 and 3. PrP is also glycosylated on two asparagine residues (Collinge 2001). 
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The unfolded N-terminal contains two important conserved regions. The first is a segment of five 
repeats of an octameric amino acid sequence (octapeptide repeat region) which contains a copper 
binding site and which, owing to its sequence characteristics, is prone to expansions resulting in 
prion diseases (Collinge 2001; Aguzzi, Sigurdson et al. 2008). The second is a hydrophobic domain 
which is thought to have an important functional role in preventing PrPC cytotoxicity: small 
deletions in this region, in fact, render PrP a potent neurotoxin (Baumann, Tolnay et al. 2007; 
Aguzzi, Sigurdson et al. 2008) . 
                                
Figure 5- Structural features of PrP.  (A) Primary structure of the murine PrP. The murine protein consists of 254 amino acid 
residues. Features include a 22 amino acid signal peptide, five octapeptide repeats, one disulphide bond (S–S) between cysteine 
residues 178 and 213, and two sites for N-linked glycosylation (CHO) at residues 180 and 196. A glycosylphosphatidylinositol (GPI) 
anchor is attached to the C-terminus of PrP from residues 231 to 254. Human PrP (not shown) has the same structural features, but 
is 253 amino acids in length (from Manson and Tuzi, 2001). (B) Tertiary structure of PrP, inserted into a lipid bilayer, including the 
unstructured N-terminal tail (gray) and the GPI anchor. The α-helices are indicated in red; the antiparallel β-sheets are shown in 
blue. The small circles represent sugar residues (from Aguzzi and Heikenwalder, 2006). 
  
21 
 
2.1 PrP FUNCTION 
 
Despite a great interest in PrP developed after the discovery of its involvement in the 
pathogenesis of TSEs, the physiological role of the protein remains unclear. Whereas its 
developmentally regulated expression in most tissues suggests a widespread function, as a matter 
of fact, PrP knock-out mice do not show any dramatic phenotype, nor the protein seems to be 
determinant for viability (McLennan, Brennan et al. 2004; Aguzzi, Sigurdson et al. 2008).  
PrP Knock-out models 
The generation of knock-out models has been one of the first steps in the attempt to unravel the 
biological role of PrP. Because of its high conservation among mammals, there was great 
expectation that the ablation of PrP would reveal the function of the gene (Steele, Lindquist et al. 
2007). However, results have been disappointing. No alterations in development, behavior and life 
expectancy were found in PrP knock-out mice, and the only evident phenotype was their complete 
resistance to prion infection (Carleton, Tremblay et al. 2001; Collinge 2001; Rangel, Burgaya et al. 
2007). 
Many different PrP-deficient mice have been generated with a wealth of strategies. For example, 
early models (Zurich and Edimburgh strains) were obtained by disrupting modifications confined 
to the ORF, and in this case, no obvious phenotype was observed (Carleton, Tremblay et al. 2001; 
Steele, Lindquist et al. 2007). 
A second knock-out strategy involved the deletion of both the coding region and its flanking 
sequences. With ageing, these mice developed a severe progressive ataxia and Purkinje cell 
degeneration. This phenotype was rescued by the reintroduction of functional PrP, and for this 
reason it was initially considered a primary consequence of the absence of the protein. Further 
studies, though, revealed that such effects were due to a knock-out artifact rather than to the lack 
of PrP. The deletion, in fact, resulted in an intergenic splicing mutation leading to the up-
regulation of a downstream protein named Doppel. This PrP-related protein shares about 25% 
homology with PrP and it is expressed in many tissues but not in the adult brain. Therefore, the 
degenerative phenotype showed by these PrP-deficient line was likely caused by the ectopic 
expression of Doppel in the brain (Carleton, Tremblay et al. 2001; Weissmann and Flechsig 2003). 
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However, despite the absence of a major phenotype, many studies identified several more subtle 
alterations both in vivo and in vitro. 
First, mice devoid of PrP showed alterations in sleep and circadian rhythms. This effect 
interestingly correlates with some features found in different prion diseases. Sleep disruption is in 
fact the main symptom in FFI, but is also increasingly recognized in sporadic and familial CJD 
(Tobler, Gaus et al. 1996; Dossena, Imeri et al. 2008). 
Other aberrations in synaptic activity, cognition and olfactory behavior were reported (see below). 
By an anatomical point of view, PrP-deficient mice showed a collateral and terminal sprouting in 
mossy fiber comparable to that observed in epilepsy. These data were complemented by others 
demonstrating an increased sensitivity to kainate-induced seizures and cell death (Rangel, Burgaya 
et al. 2007). 
Eventually, PrP knock-out neurons appeared to be more susceptible to apoptosis induced by both 
oxidative stress and serum deprivation (Kuwahara, Takeuchi et al. 1999; Vassallo and Herms 
2003). 
However, most of the described phenotypes are quite controversial: some of them have been 
contested, some others are very subtle or manifest only upon physiological challenge. One point 
of concern is that the detection of many of these phenotypes seems to depend on which strain of 
mice is used (Steele, Lindquist et al. 2007), and it is therefore very likely that all the observations 
made so far are contaminated by the confounding effects of different genetic backgrounds.  
All in all, after 30 years of extensive investigation the only straightforward characteristic of the 
knock-out mice is their resistance to prion infection, and the physiological role of PrP remains 
more mysterious than ever. 
However, based on the analysis of the mild phenotypic traits that develop in PrP knock-out mice 
and on cell culture studies, PrPC has been assigned numerous roles, the most relevant of which are 
listed below. 
Metal uptake and antioxidant activity 
PrP has been involved in metal uptake, and in particular in copper and zinc metabolism. 
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PrP is a copper (II) binding protein, having the major copper binding site located in the octapeptide 
region with a dissociation constant (Kd) of 5 µM. This Kd is compatible with the copper 
concentration released in the synaptic cleft during vesicle release. In fact, the presence of copper 
binding activity in one of the most conserved regions of the protein, the localization of the protein 
at the presynaptic membrane and the ability to bind copper at physiological concentrations argue 
for an involvement in the metabolism of this metal. 
PrP is thought to buffer copper (II) in a pH-dependent manner during vesicle exocytosis and to 
return it to the cytosol, either by transferring ions to copper transport proteins or, in case of 
higher copper concentrations, by copper-mediated PrP endocytosis (Vassallo and Herms 2003). 
Not only copper, but also zinc can bind the octapeptide region, although with a lower affinity 
(about 200 μM).  
Zinc is the most abundant trace metal in the CNS, and just like copper is contained in synaptic 
vesicles and released in the synaptic cleft during the process of neurotransmission, where it 
reaches concentrations in the millimolar range. Also in this case, therefore, the binding affinity is 
compatible with a role in binding or transporting zinc ions under physiological conditions (Watt, 
Griffiths et al., 2013). 
Moreover, PrP was evolutionary linked to Zrt/Irt-like protein (ZIP) family of transmembrane zinc 
transporters (Schmitt-Ulms, Ehsani et al. 2009). Unlike other ZIP proteins, however, PrP does not 
possess a transmembrane channel domain for direct zinc uptake. Therefore, other mechanisms 
have been proposed. For example, PrP could contribute to zinc homeostasis via endocytosis, for it 
has been shown that zinc biding triggers the internalization of the protein (Perera and Hooper 
2001). Another possibility is that PrP is a zinc sensor which mediates the uptake of the metal by 
means of other proteins. And indeed, it was found that PrP-dependent zinc uptake can be 
mediated by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) (Watt, 
Griffiths et al., 2013). 
Regulating free metal ion levels is extremely important to protect the cell from oxidative stress. In 
the presence of hydrogen peroxide, ions like iron and copper take part to Fenton redox reactions 
that generate powerful radicals such as superoxide and hydroxyl ions. Metal buffering may thus 
cooperate to prevent the generation of excessive levels of reactive oxygen species.  
24 
 
PrP antioxidant activity has been proposed based on several observations obtained from knock-
down models, such as a higher sensitivity to oxidative stress and lower activity of the main 
antioxidant enzymes like glutathione reductase and superoxide dismutase (SOD) compared to wild 
type animals. 
An actual copper-dependent SOD activity has been detected in PrP, but many observations oppose 
to this hypothesis. First, PrP copper affinity is much higher than the average affinity that is found 
in this kind of metal binding proteins, and the pH dependence of the binding between the protein 
and its catalytic ion is also unusual for a dismutase. Furthermore, PrP has been demonstrated to 
contribute only to a minor percentage of total SOD activity in the brain (Vassallo and Herms 2003). 
Cell adhesion and neurite outgrowth 
As a GPI-anchored cell surface glycoprotein, another reasonable hypothesis is that PrP may be 
involved in cell adhesion (Collinge 2001). Indeed, many of the numerous PrP-interacting partners 
that have been reported are adhesion or recognition molecules, such as the Neural Cell Adhesion 
Molecule (NCAM), the laminin receptor, the laminin receptor precursor and the extracellular 
matrix protein laminin itself. Notably, all these molecules are involved in a series of signal 
transduction pathways that regulate neurite outgrowth and neural survival and differentiation.  
And indeed, PrP is directly involved in a neuritogenesis-promoting signaling pathway. NCAM 
interacts with PrP, which is localized in lipid-enriched membrane domains. This enables NCAM to 
interact with other lipid rafts proteins to activate the downstream signaling pathways which are 
involved in neurite outgrowth and synaptic development (Chen, Mange et al. 2003; Santuccione, 
Sytnyk et al. 2005; Aguzzi, Sigurdson et al. 2008; Babus, Little et al. 2011). More details about PrP 
signaling activity are provided below. 
Myelin maintenance 
Several observations suggest that PrP may also cooperate to myelin maintenance. It was initially 
noted that some knock-out mice lines developed a late-onset peripheral neuropathy, and later PrP 
was found to be enriched in purified myelin fractions. Moreover, myelin alterations have been 
documented in some cases of GSS syndrome and in other experimental TSE models (Baumann, 
Tolnay et al. 2007; Aguzzi, Sigurdson et al. 2008; Bremer, Baumann et al. 2010). 
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Other studies found that the classical features of demyelinating neuropathies in PrP-deficient 
nerves could be abolished by rescuing PrP expression in neurons but not in Schwann cells. This 
suggests that PrP may exert an indirect protective action on myelin, taking part in the axonal 
signals which regulate Schwann cells trophism. Interestingly, the hydrophobic domain of the 
protein seems to be determinant for this role, for deletions in this region give rise to a lethal 
myelin damage in mice (Baumann, Tolnay et al. 2007; Aguzzi, Sigurdson et al. 2008; Bremer, 
Baumann et al. 2010). 
Stem cell regulation and neurodevelopment 
PrP is highly expressed during embryogenesis throughout the whole organism (Manson, West et 
al. 1992). This suggests that it may participate in developmental processes, and indeed, PrP knock-
out embryos show prominent alterations in many genes involved in development (Khalife, Young 
et al. 2011). 
In particular, PrP is involved in different aspects of stem cell biology.  
First, it regulates the self-renewal capacity of stem and progenitor cells. In the CNS, its expression 
levels correlate with the proliferation rate of both fetal and adult progenitors of the subventricular 
zone and the dentate gyrus (Steele, Emsley et al. 2006; Santos, Silva et al. 2011; Prodromidou, 
Papastefanaki et al. 2014). 
In addition, PrP expression increases as the differentiation of neural precursors proceeds, and 
maturation is delayed in the absence of the protein, suggesting a role in driving stem cell fate. 
However, neither the total number of surviving neurons nor the gross morphology of the 
hippocampus are altered in PrP knock-out mice. This indicates that proliferation rates are not the 
sole determinants of the total number of neurons in adult brain and PrP is likely to be one minor 
factor in the complex process of neurodevelopment (Steele, Emsley et al. 2006). 
Interestingly, neural stem cells are not the only lineage regulated by PrP. For example, the protein 
is highly expressed in hematopoietic stem cells (HSCs), and HSCs derived from PrP knock-out mice 
lack the ability of long-term reconstituting the hematopoietic system of lethally irradiated mice 
(Zhang, Steele et al. 2006). More recently, PrP was further shown to promote the expansion and 
engraftment of human mesenchimal stem cells (Mohanty, Cairney et al. 2012). 
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Cell survival 
Many observations support a role of PrP in cell survival which may be exerted at multiple levels.  
For example, it may be a consequence of its antioxidant activity. In this regard, it has been 
demonstrated that PrP deficient cells display enhanced sensitivity to oxidative stress-dependent 
cell death (Wong, Pan et al. 2000; Chiarini, Freitas et al. 2002).  
To confirm this hypothesis, many studies made use of focused deletions in specific regions of the 
protein to assess the effects on cell viability. Interestingly, it emerged that also some of the 
deletions outside the copper binding octapeptide region were associated to neurodegeneration. 
On the other hand, not all the ones within the octapeptide region resulted in cell death, suggesting 
that other factors besides copper-binding activity are associated with resistance to 
neurodegeneration (Chiarini, Freitas et al. 2002). 
For example, the stress-induced protein 1 (ST-1) was proposed as a ligand capable of transducing 
neuroprotective signals mediated by cAMP, protein kinase A (PKA) and Erk upon binding to PrP, 
suggesting that PrP may function as a neurotropic receptor (Chiarini, Freitas et al. 2002).  
A putative neuroprotective activity was also hypothesized after observing that PrP is upregulated 
in the penumbra region in hypoxic brain injuries, and that ischemic lesions are larger in PrP-
deficient than in wild type mice (McLennan, Brennan et al. 2004).  
Different molecular mechanisms mediate neuronal cell death after focal cerebral ischemia in vivo. 
In addition to excitotoxicity and neuroinflammation, both oxidative stress and apoptosis 
contribute to neuronal loss. Given the antioxidant and anti-apoptotic function of PrPC in cultured 
neurons, it is tempting to speculate that early upregulation of PrPC after focal cerebral ischemia 
may be part of an adaptive cellular response promoting neuronal survival after ischemic injury. 
(Weise, Crome et al. 2004). 
A direct anti-apoptotic function for PrP was also proposed. First, PrP deficient neurons were found 
to be more susceptible to apoptosis induced by serum deprivation, and this phenotype could be 
rescued by overexpression of either PrP or Bcl-2, a very well-known anti-apoptotic protein 
(Kuwahara, Takeuchi et al. 1999). 
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Second, a soluble cytosolic form of PrP was demonstrated to interact with some Bcl-2 family 
members (Kurschner and Morgan 1996). In addition, a certain degree of homology was found 
between PrP and the Bcl-2 homology domain 2 (BH2). Importantly, BH2 is a crucial domain for the 
anti-apoptotic function of Bcl-2 and for its interaction with the pro-apoptotic Bax protein. 
All these clues eventually led to identify a direct anti-Bax effect of PrP, and the anti-apoptotic 
properties of PrP were demonstrated to be comparable in extent to the classic anti-apoptotic 
protein Bcl-2 (Bounhar, Zhang et al. 2001).  
PrP as a signaling molecule 
Through its broad range of functions, PrP appears to be connected with nearly all aspects of 
neuronal physiology. But how can a single protein serve so many different functions without being 
indispensable? A possible answer could be that PrP is a signaling molecule involved in the 
regulation of many redundant pathways. 
In support to this hypothesis there is the evidence that PrP interacts with an impressive number of 
different membrane proteins, potentially influencing their localization and activity. As already 
mentioned, it also segregates in sphingolipids- and cholesterol-rich membrane microdomains 
known as lipid rafts. Thanks to their peculiar lipidic composition, lipid rafts bring together 
receptors, second messengers and effectors, working as bona fide “signal transduction centers”.  
All these aspects are indeed consistent with a possible role of PrP as a signaling molecule, which 
may work as a receptor, a co-receptor or even a ligand able to induce signal transduction 
pathways (Hirsch, Hernandez-Rapp et al. 2014). 
Several putative ligands for PrP have been identified so far. The most important have been 
mentioned previously, and include vitronectin, laminin and ST-1 (Hirsch, Hernandez-Rapp et al. 
2014). Notably, also amyloid precursor protein (APP) and Aβ oligomers can bind PrP with high 
affinity, conferring to this protein a relevant role also in the pathogenesis of Alzheimer disease 
(Lauren 2014). Ligand binding may trigger PrP clustering, thereby activating the signaling activity, 
as it occurs for other GPI-anchored proteins. 
Over the years, many possible downstream effectors were described, including phosphoinositide 3 
kinase (PI3K), PKA, the reactive oxygen species (ROS)-generating enzyme NADPH oxidase, the 
glycogen synthase kinase GSK3b, the mitogen-activated protein (MAP) kinases ERK1/2 and the Src 
28 
 
kinases members Fyn and Lyn (Hirsch, Hernandez-Rapp et al. 2014). Among these, Fyn kinase is 
probably the main PrP effector, which controls most of the above-mentioned pathways and is 
involved in both prion and Aβ-induced neurotoxicity (Ochs and Malaga-Trillo 2014). 
As a GPI-anchored extracellular protein, PrP is not able to directly induce intracellular signaling 
cascades, but requires a partner. In 2000, Mouillet-Richard and colleagues identified caveolin as a 
possible intermediate factor linking PrP with Fyn kinase (Mouillet-Richard, Ermonval et al. 2000). 
Fyn and the Src kinases are involved in a wide range of cellular processes, including cell 
differentiation, proliferation, adhesion, migration and survival (Roskoski 2004), and most of the 
functions attributed to PrP depend on the activity of proteins that are indeed regulated by Src 
kinases.  
On the other hand, all these general processes are controlled by a very complex network of 
redundant pathways, each of which can easily compensate for defects in the others. This may 
likely be the reason why a loss of function of PrP does not produce any remarkable effect. 
A role for PrP as a signal transducer of a broad set of redundantly controlled pathways could 
hence fit quite well to a protein which “is implicated in virtually everything, but responsible for 
nothing” (Veasey, Fornal et al. 1995). 
 
2.2 PRION GENERATION 
 
The key event in the development of the disease-causing particle is the conversion of the normal 
PrPC into the aberrant isoform PrPSc.  
Although identical in sequence and post-translational modifications, the two isoforms show 
marked differences in their biochemical properties: PrPC has an α-helix-rich structure, is sensitive 
to proteinase K (PK) and is soluble, whereas PrPSc is rich in β-sheets, partially resistant to PK 
digestion and prone to aggregation, being insoluble in non-ionic detergents (Aguzzi, Sigurdson et 
al. 2008). 
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Prion propagation is thought to occur by a template-assisted process in which PrPSc acts as a 
template onto which PrPC is refolded into the pathological conformation. During this process PrPC 
may need to acquire a  partially unfolded structure to interact with PrPSc, an intermediate state 
which is referred to as PrP* (Colby and Prusiner 2011). Conversion may then occur either through 
an autocatalytic event induced by a heterodimeric association of PrP* and PrPSc or through a non-
catalytic, nucleated polymerization process.  
In the former case, the conformational change of PrPC into PrPSc would be prevented in standard 
conditions due to a high activation energy. The energy barrier would be lowered by the 
association of PrPSc to PrPC, thus permitting the autocatalytic conversion.  
The alternative model proposes that conversion of PrPC into PrPSc is a reversible process, but the 
equilibrium is strongly in favor of the native conformation. PrPSc can form and stabilize only when 
it adds onto a crystal-like seed or aggregate of PrPSc. Once a seed is present, further monomer 
addition is accelerated (Aguzzi, Sigurdson et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 6- Structural features and biochemical properties of PrP isoforms. The C-terminal globular domains of (A) PrPC and (B) 
PrPSc are represented in the upper frame. The normal isoform represented in (A) contains mostly α-helices (indicated in red), 
whereas in the pathogenic form shown in (B) has a high content of β-sheets. The lower table summarizes the biochemical 
properties associated to either isoform (from Aguzzi and Polymenidou, 2004). 
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Figure 7- Models of PrP conversion. There are two proposed models for the conversion of the normal prion protein (PrPC) into the 
infectious form (PrPSc). (A) An interaction between PrPSc and PrPC, induces the latter to transform itself into further PrPSc  through 
an autocatalytic process. Spontaneous conversion to the infectious form does not normally occur due to a high energy barrier 
between the two isoforms. (B) The conversion of PrPC and PrPSc is a reversible process, but at equilibrium strongly favors the 
conformation of PrPC. Converted PrPSc is maintained only when it adds onto a fibril-like seed or aggregate of PrPSc. Once a seed is 
present, further monomer addition is accelerated. PrPSc can therefore aggregate to form amyloid, and this can fragment to form 
several infectious seeds (from Aguzzi and Polymenidou, 2004). 
 
These profound structural transitions may also require the activity of other proteins such as 
chaperones. Several pieces of evidence support the idea that a cofactor may actually exist but, 
lack of experimental demonstration. This proposed molecule, defined as ”Protein X”, is thought to 
bind to PrPC facilitating its interaction with PrPSc (Prusiner 1998; Aguzzi, Sigurdson et al. 2008). 
Prion propagation is likely to occur either in late-endosomes or in lysosomes, where PrP is recycled 
after endocytosis. The environment of these organelles promotes protein unfolding at low pH 
prior to degradation by acid-activated proteases. According also to in vitro studies, it is thus 
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possible that PrP conversion may occur at this level, facilitated by reducing and moderately acidic 
milieu (Collinge 2001). 
 
2.3 MECHANISMS OF NEURODEGENERATION 
 
Gain versus loss of function 
The nature of prions, their biochemical properties and the mechanisms by which they propagate 
are now reasonably well understood. In contrast, much less is known about how PrP misfolding 
induces neuronal death. 
Neurodegeneration, that sometimes is restricted to specific neuronal subpopulations, may occur 
either because of a toxic gain of function or a loss of the physiological function of the protein. 
Most likely, as suggested below, it can result by a combination of the two (Winklhofer, Tatzelt et 
al. 2008). 
The fact that the inactivation of the PrP gene does not produce any effect on neuronal viability, 
together with the dominant modality of inheritance of genetic prion diseases tend to exclude that 
these disorders arise because of a simple loss of the physiological function of PrP (Solomon, 
Schepker et al. 2010). 
Several experimental observations support the hypothesis of a gain-of-function mechanism. For 
example, the presence of intra-axonal aggregates of misfolded PrP was shown to contribute to 
neuronal death by disrupting axonal transport (Medrano, Barmada et al. 2008). In addition, in vivo 
crosslinking of PrPC by antibodies triggers neuronal apoptosis, and, as previously mentioned, 
mutants lacking the hydrophobic domain of the protein (PrPΔHD) have neurotoxic effects 
(Winklhofer, Tatzelt et al. 2008). To explain the latter finding it was proposed that PrPΔHD may 
block some kind of neurotrophic signaling by binding to an unknown receptor (Shmerling, Hegyi et 
al. 1998). Alternatively, PrPΔHD may compete with PrPC for binding to a signal-transducing 
protein. In this scenario, whereas PrPC induces neuroprotective signaling, binding of PrPΔHD 
triggers a neurotoxic cascade (Li, Christensen et al. 2007).  
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However, Li et al demonstrated that the toxic effect of these mutants could be reversed by co-
expressing wild type PrP, and observed that a disease-associated mutation impaired the efficiency 
of the protein in rescuing the phenotype. In addition, PrP was shown to attenuate the activity of 
N-methyl-D-aspartate receptors (NMDARs), with PrP knock-out neurons being more susceptible to 
glutamate-induced excitotoxicity (Khosravani, Zhang et al. 2008).  
Taken together, these data indicate that a loss-of-function of PrP may also be detrimental in 
specific contexts. For example, whereas its biological activity is normally dispensable, it may 
become essential in the disease under cellular stress conditions (Solomon, Schepker et al. 2010).  
According to this view, PrPSc might not be toxic per se: it may rather exert a dominant-negative 
effect on PrPC, either by converting it in an inactive form or  by competing for the interaction with 
its endogenous ligands (Hetz, Maundrell et al. 2003).  
Insights from the mutants 
Considerable evidence now suggests that aggregation, infectivity and toxicity are distinct 
properties of PrP that do not necessarily coincide. This concept is exemplified by the existence of 
several mutants that produce spontaneous neurodegeneration in humans and/or transgenic mice 
without the formation of infectious PrPSc.  By isolating the neurotoxic effects of PrP from prions, 
these mutants have provided important - although not completely conclusive- insights into 
possible pathogenic mechanisms (Solomon, Schepker et al. 2010).  
Such mutants can be grouped into two categories. 
First, there are the mutations linked to familial prion diseases. When expressed in transfected cells 
or transgenic mice, these mutants generally display some tendency to aggregation and protease 
resistance similar to PrPSc, and sometimes their pathogenic properties actually depend on the 
toxicity of oligomeric aggregates (Medrano, Barmada et al. 2008). However, they also display 
other properties that may be responsible for neuronal dysfunction, such as altered trafficking and 
cellular localization (Ivanova, Barmada et al. 2001) and, possibly, aberrant interaction or loss of 
interaction with partner proteins. Interestingly, there are also cases in which these mutants are 
identical to wild type PrP in terms of biochemical properties and cellular localization (Harris 2003), 
suggesting that prion generation and aggregation are not mandatory for the establishment of the 
pathology.  
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The second category includes a variety of artificially-generated mutants. Among these variants, 
the partial deletions of the protein are particularly interesting. Most of these mutant proteins 
possess a powerful neurotoxic effect without showing PrPSc-like properties such as aggregation, 
protease resistance and infectivity. In some cases, moreover, toxicity is suppressed in the presence 
of wild type PrP, indicating that the two proteins may compete for the binding to a common 
target, with opposite effects on neuronal viability (Shmerling, Hegyi et al. 1998; Li, Christensen et 
al. 2007; Solomon, Schepker et al. 2010). 
Combined with the evidence that PrP is a neuroprotective molecule, results obtained on artificial 
and naturally-occurring mutants suggest that neurotoxicity in prions may ultimately be caused by 
a subversion of the function of PrPC. Specifically, the interaction with PrPSc or other aberrant 
intermediates may alter the physiological activity of the normal protein (Harris and True 2006; 
Solomon, Schepker et al. 2010). This would then result in cell death because of the suppression of 
fundamental neuroprotective signals or the direct generation of neurotoxic stimuli. Given the 
ability of PrP to interact with numerous partners, this functional subversion may also result in 
further “side effects” caused by alterations of these proteins, which, independent of PrP itself, are 
important for neuronal function. 
Conclusions 
Based on what discussed so far, it is evident that prion diseases are not a homogeneous class of 
diseases. Although pathogenicity is always attributable to a single protein, in fact, many 
differences exist among the various diseases. 
As already pointed out, for example, whereas classic TSEs are defined by the presence of PrPSc and 
transmissibility, some of the inherited forms do not possess these features. In this view, probably, 
a distinction should be made between classic prion diseases and prion proteinopathies 
(Wadsworth, Asante et al. 2010). 
In some cases, prions or prion-like aggregates, are the key neurotoxic intermediates. But in other 
cases, the toxicity of PrP goes beyond prions, and most likely depends on a subversion of the 
function of PrPC (Solomon, Schepker et al. 2010). 
In general, there are several toxic pathways that can be activated by the abnormal prion protein. 
These include corruption of PrP interactions at the cell surface, impairment of secretory protein 
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transport and axonal transport, dysregulation of proteostatic cellular responses and induction of 
endoplasmic reticulum stress, constitutive recruitment of downstream effectors, alteration of cell 
membrane properties, and possibly other that are yet to be identified (Medrano, Barmada et al. 
2008; Senatore, Restelli et al. 2013; Hirsch, Hernandez-Rapp et al. 2014; Chiesa 2015). These 
mechanisms are likely to co-exist, but may contribute differently to pathogenesis in different prion 
diseases (Chiesa 2015). 
This complex neurotoxic modality is probably one of the keys of the phenotypic heterogeneity of 
prion diseases, and has fundamental implications in therapy. Most current approaches to 
treatment of prion diseases aim at inhibiting accumulation of PrPSc (Trevitt and Collinge 2006). 
Identification of cellular pathways activated by neurotoxic forms of PrP or drugs that stabilize the 
native conformation of the protein would presumably allow development of more specific and 
effective therapies (Solomon, Schepker et al. 2010; Chiesa 2015).  
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3. THE PRION PROTEIN AND THE SYNAPSE 
 
3.1 THE SYNAPSE 
 
The synapse is the functional connection between neurons, or between a neuron and another 
type of cell. Within the CNS, a typical neuron possesses several thousand of these contacts. Most 
synapses connect axons to dendrites, but contacts may also be created between different parts of 
the neuron, generating axo-somatic, axo-axonic, and dendro-dendritic synapses. On the basis of 
the transmission mechanism, these structures are classified into electrical or chemical synapses, 
the latter being the most abundant in mammalian CNS. 
Chemical synapses allow the transfer of information from a presynaptic to a postsynaptic cell and 
are therefore asymmetric in structure and function. The presynaptic terminal is a specialized area 
within the axon of the presynaptic cell that contains neurotransmitter enclosed in synaptic 
vesicles, as well as a number of other supporting structures and organelles, such as mitochondria 
and endoplasmic reticulum. Synaptic vesicles are organized into different pools on the basis of 
their availability to be released: the ready releasable pool, readily available on stimulation, the 
recycling pool, which maintains constant the number of releasable vesicles upon moderate 
stimulation, and the reserve pool, which  contains the highest number of synaptic vesicles in the 
terminal and works as a storage from which vesicles can be mobilized only under certain 
conditions (Jahn and Fasshauer 2012). 
Immediately opposite is a region of the postsynaptic cell containing neurotransmitter receptors. In 
excitatory synapses, this region consists of an elaborate complex of many different proteins called 
the postsynaptic density (PSD). Proteins in the PSD are involved in anchoring and trafficking 
neurotransmitter receptors and modulating their activity, as well as in organizing the signaling 
proteins which also participate to neurotransmission (Sheng and Kim 2011). 
The release of neurotransmitter is triggered by the arrival of an action potential at the presynaptic 
terminal. The membrane depolarization induced by the action potential opens the voltage-gated 
calcium channels (VGCCs) resulting in a massive calcium influx into the terminal. Calcium ions then 
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induce the fusion of docked vesicles with the presynaptic membrane, and the release of their 
content into the synaptic cleft. 
Receptors on the opposite side of the synaptic gap bind neurotransmitter molecules, responding 
in either of two general ways. First, the receptors may directly open ligand-gated ion channels in 
the postsynaptic cell membrane, causing ions to enter or exit the cell and changing the local 
transmembrane potential. These receptors are called ionotropic receptors. The resulting change in 
voltage is called a postsynaptic potential, and can be excitatory (resulting from membrane 
depolarization) or inhibitory (resulting from membrane hyperpolarization) depending on which 
kind of ion channel conducts the current. The second way a receptor can affect membrane 
potential is by modulating the production of second messengers. These receptors are called 
metabotropic receptors, and their responses are normally slower and more long-lasting compared 
to ionotropic receptors. 
After being released, the neurotransmitter must be removed from the synaptic cleft to ensure 
proper duration of stimulation. This removal can occur by simple diffusion, by enzymatic cleavage 
or through reuptake into neurons and glia.  
Synapses in the CNS are mainly integrative. This means that a single synaptic event alone is not 
able to trigger a response in the postsynaptic neuron. The overall response to synaptic stimulation 
depends on the integration of excitatory and inhibitory inputs which occur at the same time in the 
cell: only when the sum of excitatory postsynaptic potentials (EPSPs) overcomes the effect of the 
sum of inhibitory postsynaptic potentials (IPSPs) the threshold for initiating an action potential can 
be reached and the nervous signal propagated. 
Excitatory synapses 
An excitatory synapse is a synapse in which an action potential in the presynaptic neuron increases 
the probability of an action potential occurring in the postsynaptic cell. Excitatory synapses are 
usually situated on dendritic spines, specialized membrane protrusions in which receptors and 
PSDs are concentrated. 
Glutamate is the most common excitatory neurotransmitter within the CNS, and it exerts its 
function by binding to both ionotropic and G protein-coupled metabotropic receptors. 
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NMDA and AMPA receptors are the two main kinds of ionotropic glutamate receptors. They have 
different physiological properties and often coexist at the same synapse. 
AMPA receptors 
AMPA receptors mediate the vast majority of fast excitatory neurotransmission, and are therefore 
the main responsible for signal propagation in the CNS.    
They are composed of four types of subunits, GluA1 to GluA4, which combine to form tetramers. 
Most AMPA receptors are heterotetrameric, consisting of two dimers of GluA2 and either GluA1, 
GluA3 or GluA4, with the relative abundance of the different subunits varying across brain regions.  
Each subunit has an identical membrane topology. The amino terminus is extracellular, and there 
are three membrane-spanning domains, one re-entrant loop domain and an intracellular 
C-terminal domain. This C-terminal domain is a highly variable region that provides a platform for 
both the protein interactions and the post-translational modifications that regulate subunit-
dependent trafficking and function (Schwenk, Baehrens et al. 2014; Henley and Wilkinson 2016).  
AMPARs are permeable to cations such as sodium, potassium and calcium, and the selectivity of 
this permeability is governed by the GluA2 subunit. Specifically, the presence of GluA2 renders the 
channel impermeable to calcium. This is determined by post-transcriptional modification (RNA 
editing) of the arginine (R)/glutamine (Q) editing site of the GluA2 mRNA. Here, an adenosine is 
deaminated to form hypoxantine, changing the uncharged amino acid glutamine to the positively-
charged arginine in the receptor's ion channel (Higuchi, Single et al. 1993). The presence of a 
positively-charged amino acid at this site hampers calcium influx through the pore. Most AMPARs 
in the adult brain contain the GluA2 subunit, and more than 95% of the GluA2 transcripts are 
edited. This means that the principal ions gated by AMPARs are normally only sodium and 
potassium (Isaac, Ashby et al. 2007; Mayer 2011). 
However, GluA2-lacking, calcium-permeable AMPARs are also present, and may play a critical role 
in different processes. For example, they are highly expressed during early postnatal development 
and during the early phases of several forms of synaptic plasticity, and are constitutively present in 
certain neuronal subpopulations such as inhibitory interneurons (Geiger, Melcher et al. 1995; 
Kumar, Bacci et al. 2002; Henley and Wilkinson 2016).   
38 
 
   
Figure 8- AMPA receptors. AMPA receptors are tetramers that can comprise any combination of GluA1–GluA4 subunits but usually 
contains GluA2. Receptors containing edited GluA2 are impermeable to calcium (left). AMPA receptors containing unedited GluA2 
and AMPA receptors lacking GluA2 are calcium-permeable (right) (modified from Wright and Vissel 2012). 
 
NMDA receptors 
NMDA receptors are heteromeric complexes incorporating different subunits grouped in three 
main types: GluN1, GluN2 and GluN3. The GluN2 family comprises four different proteins (GluN2-
A, -B, -C and -D) and the GluN3 family two (GluN3-A and -B). The receptor is formed as a tetramer 
with two obliged GluN1 subunits associated to two GluN2, or a mixture of GluN2 and 3 subunits 
(Paoletti, Bellone et al. 2013). 
In contrast to AMPARs, NMDARs mediate a slow, indirect form of excitation which results from the 
modulation in the number and the strength of AMPARs (Horak, Petralia et al. 2014). 
Activation of NMDARs requires the presence of both glutamate and a co-agonist (glycine or D-
serine), which bind to the GluN2 and GluN1 subunits, respectively. However, NMDARs are silent 
under resting conditions.  The ion channel is in fact normally blocked by a magnesium ion which 
can be removed only when the membrane is depolarized by concomitant postsynaptic activity. In 
other words, when a weak activation of the presynaptic neuron causes the release of glutamate 
from the axon terminal, the neurotransmitter binds to both AMPARs and NMDARs, but it is only 
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able to activate the former, resulting in a slight depolarization of the postsynaptic neuron. Given a 
stimulus of sufficient strength, AMPARs can depolarize the membrane sufficiently to expel the 
magnesium ion from the NMDAR channel, thereby activating the receptor.  
NMDARs, like AMPA receptors, are non-specific cation channels, and their activation results in a 
flux of sodium, potassium and calcium. In particular, calcium entering the postsynaptic terminal 
through these receptors initiates various metabolic pathways that ultimately affect the strength of 
the synapse, a process known as synaptic plasticity (see below). Most commonly, these pathways 
result in changes in the number and properties of AMPARs (Horak, Petralia et al. 2014). 
                             
  
Figure 9- NMDA receptors. NMDARs contain two GluN1 and two GluN2 (or GluN3) subunits, which assemble as a tetramer. The 
binding sites for agonists (glutamate and NMDA) and co-agonist (glycine and D-serine) are shown. Note that the channel is blocked 
by a magnesium ion at resting membrane potentials. 
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Dendritic spines 
Dendritic spines are membranous protrusions from the neuronal surface generally consisting of a 
head connected to the neuron by a thin neck. They are postsynaptic structures specialized for 
optimizing neurotransmission which receive inputs specifically from glutamatergic neurons. More 
than 90% of excitatory synapses in the CNS terminate on spines, which are mostly located on the 
dendrites (Nimchinsky, Sabatini et al. 2002). 
The head of a spine contains the PSD, neurotransmitter receptors, cytoskeletal and adaptor 
proteins, and associated signaling molecules. The role of PSD is to concentrate the receptors close 
to the active zone of the presynaptic element and to organize the postsynaptic apparatus in order 
to maximize the efficiency of neurotransmission (Rochefort and Konnerth 2012). Segregation of 
the PSD in the spine serves to compartmentalize the neurotransmission apparatus to further 
optimize its function. The presence of a narrow neck, in fact, allows to concentrate signaling 
molecules and to impair diffusional exchanges between spine and the rest of neuron. This 
property is very suitable for guaranteeing the specificity of synapse activation, especially during 
the signal transduction events regulating single-synapse plasticity (Nimchinsky, Sabatini et al. 
2002). 
Dendritic spines are characterized by morphological diversity. The most common classification 
criterion divides spines into three major types: mushroom spines, which have a large head and a 
narrow neck, thin spines with a smaller head and a narrow neck and stubby spines, whit no 
conspicuous constriction between the head and the attachment to the neuron.  
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Figure 10- Diversity of spine shape. (A) 3D reconstruction of a dendrite of a hippocampal pyramidal neuron. Representative images 
of (B) stubby, (C) mushroom and (D) thin spines. Scale bar: 1 μm (from McKinney 2010). 
 
Spines change significantly during development. Neonatal dendrites are relatively bare. 
Subsequently, the number of spines increases greatly and eventually a process of pruning 
produces a loss of spines to reach the mature spine density. In the adult brain, mushroom spines 
are the most abundant type. However, spine morphology does not necessarily correlate with spine 
maturity, which is rather associated with the presence of a well-developed inner apparatus 
(Nimchinsky, Sabatini et al. 2002). 
Spines and synapses are dynamic structures that undergo continuous turnover throughout the 
whole life span: they are constantly formed and eliminated, and they undergo profound structural 
modifications as a function of synaptic activity. (De Roo, Klauser et al. 2008). Such  plasticity tends 
to decrease with age: in adulthood most spines remain persistent, and the half-life of spines 
increases (Alvarez and Sabatini 2007). 
Synaptic plasticity 
One of the most important characteristics of synapses is their ability to respond to changes in the 
incoming patterns of stimuli by modifying their strengths. This fundamental property allows the 
continuous changes in the efficacy of neurotransmission and neuronal connectivity that are at the 
basis of the highly adaptable nervous system of vertebrates. 
Synaptic plasticity exists in many forms which differ in terms of duration, triggering stimuli and 
molecular mechanisms. In all cases, changes in synaptic strength are achieved through 
modifications in two general parameters: the efficacy of neurotransmitter release at the 
presynaptic side and the sensitivity of the postsynaptic compartment, which in turn depends on 
modifications in the number, type and properties of neurotransmitter receptors (Anggono and 
Huganir 2012). 
Particularly interesting for the magnitude of their effects and for their relevance in brain pathology 
are the durable forms of plasticity. They are in fact believed to be the molecular substrates of 
learning and memory, and alterations in these processes are present in many neurodegenerative 
conditions, including prion diseases (Johnston, Fraser et al. 1998). 
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Among the most studied forms of synaptic plasticity are Long-Term Potentiation (LTP) and Long-
Term Depression (LTD), which affect synaptic strength in opposite directions. Induction of these 
forms of plasticity, also known as Hebbian plasticity, is associative in requiring correlated firing of 
the pre- and postsynaptic neurons and depends on the activation of NMDARs. The resulting 
change in synaptic strength is rapid, specific to individual synapses and can last from hours to 
months (Lee, Escobedo-Lozoya et al. 2009). Moreover, Hebbian plasticity produces positive-
feedback processes. For example, once LTP is induced, potentiated synapses can undergo further 
potentiation with greater ease. This mechanism of course has developed to facilitate the 
reinforcement of significant stimuli, but without a proper counterbalance it may drive neuronal 
activity to saturation or to unstable states prone to hyperexcitation (Turrigiano 2008). 
To prevent these side effects, other homeostatic forms of synaptic plasticity operate as 
compensatory, negative feedback mechanisms to maintain network stability (Vitureira and Goda 
2013). In contrast to Hebbian plasticity, homeostatic plasticity is generally considered to be a slow 
process elicited by global changes in network’s activity and inducing global modifications so that 
all the synapses of a given neuron are scaled equally. In this way, the overall excitability of the 
network is maintained within an optimal working range and the relative differences in synaptic 
strength resulting from Hebbian plasticity are preserved (Turrigiano 2008; Vitureira and Goda 
2013).  
 
3.2 SYNPATIC INVOLVMENT IN NEURODEGENERATION 
 
Synapse loss: a key hallmark of neurodegeneration 
Neurodegeneration is a complex phenomenon which results from the synergistic effect of several 
pathogenic mechanisms. Accumulation of neurotoxic substances, inflammation, oxidative stress, 
autophagy, protein degradation and mitochondrial dysfunction are only some examples, which are 
often present together in different neurodegenerative conditions. However, it remains unclear 
whether they are the cause of the disease or a consequence of the primary damage. 
Whatever the triggers may be, synapse loss appears to be a major pathophysiological hallmark 
shared by all neurodegenerative diseases (Lu, Nagappan et al. 2013). More specifically, alterations 
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of the excitatory synapses are normally early events that strongly correlate with the 
symptomatology even when neuronal death is not yet evident. For this reason, neurodegenerative 
disorders are included in the heterogeneous group of the so-called “synaptopathies”, a term 
which refers to brain disorders which arise from synaptic dysfunction (Lepeta, Lourenco et al. 
2016). 
 This, of course, applies also to prion diseases and is supported by a wealth of evidence. For 
instance, synaptic changes correlate with early behavioral signs in scrapie infected mice (Jeffrey, 
Halliday et al. 2000), and local accumulation of PrPSc is associated with loss of presynaptic 
compartments and dendritic atrophy before neuronal death occurs (Clinton, Forsyth et al. 1993). 
Moreover, synaptic alterations have been described in several sporadic or inherited cases of CJD 
(Ferrer 2002). 
Other studies reported that impaired synaptic responses associated with early cognitive, 
behavioral and motor deficits occur before extensive PrPSc deposition and neuronal loss 
(Cunningham, Deacon et al. 2003; Senatore, Colleoni et al. 2012), and depend on defective 
depolarization-induced glutamate exocytosis due to altered calcium influx (Senatore, Colleoni et 
al. 2012). Interestingly, it was also observed that deletion of the pro-apoptotic gene Bax prevents 
the death of cerebellar granule neurons in a mouse model of inherited prion disease (Tg(PG14) 
mice), but does not affect the development of clinical symptoms, nor synaptic shrinkage and loss 
(Chiesa, Piccardo et al. 2005), reinforcing the hypothesis that pathological signs are somehow 
independent of neuronal loss at least in the first stages of the disease. 
On the other hand, it is now widely agreed upon that synaptic activity is also essential to promote 
neuronal health and survival (Bell and Hardingham 2011), suggesting that the relationship 
between synaptic dysfunction and neurodegeneration may not be simply correlative, but causal. 
It is known, for instance, that neurotransmission can activate neurotrophic signaling pathways, the 
blockade of which may result in a dangerous lack of survival stimuli (Mennerick and Zorumski 
2000). In some cases, the situation is more complex. For example, NMDARs may activate either 
neurotrophic or apoptotic cascades depending on their localization: whereas synaptic receptors 
transduce pro-survival signals, extrasynaptic receptors are coupled to neurotoxic pathways. In this 
case, thus, is the balance in receptor distribution to be critical for determining neuronal fate 
(Hardingham and Bading 2010), and the loss of synaptic sites may clearly alter this balance. 
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Calcium-permeable receptors and excitotoxicity 
If, on the one hand, loss of synaptic activity is emerging as a major determinant of neuronal 
pathology in neurodegeneration, on the other hand an excessive, uncontrolled activation of the 
excitatory synapses can be detrimental for neuronal survival just as much.  
Excitotoxicity is the pathological process by which neurons are killed by the toxic action of 
excitatory neurotransmitters such as glutamate, and indeed, many lines of evidence demonstrate 
an increased or deregulated glutamatergic transmission in several neurodegenerative diseases 
(Dong, Wang et al. 2009). 
Overactivation of glutamate receptors can damage neurons in several ways. For example, acute 
excitotoxicity is thought to be mediated by an osmotic imbalance occurring when high amounts of 
water follow the exaggerated sodium and chloride influx caused by a sustained membrane 
depolarization (Dong, Wang et al. 2009). 
However, the most relevant mechanism of excitotoxicity is the disruption of cellular calcium 
homeostasis. This is a direct consequence of the excessive calcium influx through NMDARs and 
calcium-permeable AMPARs. Uncontrolled rises in intracellular calcium levels result in 
inappropriate activation of calcium-dependent processes that are normally dormant or operate at 
low levels, causing metabolic impairment and eventually cell death. Typically, rapid increases in 
calcium loads activate proteases, lipases and other catabolic enzymes that trigger neurotoxic 
signaling cascades. These events include mitochondrial membrane depolarization, caspase 
activation and generation of oxygen and nitrogen free radicals which ultimately lead to apoptosis 
or necrosis (Arundine and Tymianski 2003; Dong, Wang et al. 2009). 
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3.3 PrP AS A REGULATOR OF SYNAPTIC FUNCTION  
 
The idea that PrP is a synaptic protein is supported by several observations. 
The fact itself that PrP is predominantly located at both pre- and the postsynaptic terminals 
suggests that it may be involved in regulating synaptic activity (Fournier 2008; Steinert 2015). 
Moreover, PrP complex interactome comprises many synaptic proteins, some of which are directly 
involved in synaptic transmission. They include the pre-synaptic synapsin 1 and synaptophysin, 
many neurotransmitter receptors such as ionotropic and metabotropic glutamate receptors, 
serotoninergic receptors and the nicotinic α7 receptor, and ion channels such as VGCCs (Fournier 
2008; Senatore, Restelli et al. 2013; Hirsch, Hernandez-Rapp et al. 2014). Although not directly 
involved in neurotransmission, other interactors have a well-established synaptic role, such as the 
adhesion molecule NCAM and the signaling protein Fyn (Fournier 2008; Um, Nygaard et al. 2012; 
Hirsch, Hernandez-Rapp et al. 2014; Ochs and Malaga-Trillo 2014). 
PrP and neurotransmission 
In addition to the general considerations regarding PrP localization and interactions, a wealth of 
experimental data indicates a direct role of this protein in regulating neurotransmission. 
Most evidence comes from studies in PrP knock-out models. Notably, the only clear abnormalities 
that were found in these animals were always ascribable to alterations in neurotransmission or to 
correlated behavioral traits. 
For example, one of the first studies assessing synaptic function in PrP knock-out mice found a 
reduction in the amplitude of hippocampal inhibitory postsynaptic currents and a depolarizing 
shift in their reversal potential, suggesting a weakened GABAA receptor-mediated fast inhibition 
which could explain the epileptic-like activity seen in CJD patients (Collinge, Whittington et al. 
1994). 
Another general evidence was obtained in a study showing a direct correlation between PrPC 
expression levels and the entity of evoked excitatory synaptic responses. This finding also entails 
that changes in the amount of PrPC may influence hippocampal synaptic transmission (Carleton, 
Tremblay et al. 2001). Accordingly, defects in hippocampal LTP in PrP-deficient mice were found in 
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multiple studies (Collinge, Whittington et al. 1994; Maglio, Martins et al. 2006; Rangel, Madronal 
et al. 2009). 
In addition, a reduction of slow afterhyperpolarization, a specific component of the 
hyperpolarizing phase of a neuron which can be evoked by trains of action potentials, was 
observed following acute knock-out of PrP, supporting the idea of a direct role of the protein in 
the modulation of synaptic transmission (Mallucci, Ratte et al. 2002). 
Some behavioral aspects that can be considered important functional correlates of abnormal 
synaptic transmission have also been reported. In addition to the already mentioned alterations in 
circadian rhythm and olfactory behavior, PrP knock-out mice exhibit specific cognitive deficits in 
hippocampal spatial learning which can be rescued by restoring PrP expression in neurons (Criado, 
Sanchez-Alavez et al. 2005). Even more interesting was the finding that the M129V polymorphism 
affects long-term memory in humans, with individuals carrying the MM genotype performing 
better than those with the VV genotype (Papassotiropoulos, Wollmer et al. 2005). 
More recently, other works have suggested specific synaptic roles for PrP, two examples of which 
are described below. 
The first example indicates a direct presynaptic involvement in neurotransmission. A study from 
Senatore et al. demonstrated that PrP interacts with the VGCCs α2-δ1 subunit, an important 
component which promotes the anterograde trafficking of the channel. The authors also 
demonstrated that a mutant variant of the protein, the PG14 PrP, is retained in the endoplasmic 
reticulum, and its interaction with α2-δ1 subunit determines the intracellular retention of the 
whole channel complex, resulting in reduced membrane delivery of the VGCCs. This is responsible 
for the lower depolarization-induced calcium influx and the consequent low glutamate release 
observed in Tg (PG14) mice, and is thought to be at the origin for early motor and behavioral 
symptoms in these animals (Senatore, Colleoni et al. 2012). 
A second interesting example, on the contrary, suggests a postsynaptic function for PrP. In a work 
from Koshravani et al, PrP deficiency was found to be associated to a strong enhancement of 
synaptic NMDAR currents, which displayed greater amplitude and prolonged decay time. PrP was 
also found to co-immunoprecipitate with the GluN2D subunit of the receptor, indicative of a direct 
role of the protein in downregulating NMDAR activity. Since PrP-deficient neurons were found to 
be more susceptible to NMDAR-mediated cell death, these data suggest that the putative 
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neuroprotective function of PrP may be exerted by inhibiting NMDAR excitotoxic potential 
(Khosravani, Zhang et al. 2008). 
Pathological consequences 
The concept that PrP is a synaptic protein supports the idea that prion diseases may originate from 
synaptic dysfunction, and neurodegeneration may follow as a consequence of disrupted neuronal 
activity. 
Indeed, a wealth of data demonstrates that synapse loss is one of the first neuropathological 
events in prion diseases. Dendritic abnormalities and spine loss have been observed early during 
the pre-symptomatic phase of the disease, in the absence of evident PrPSc deposition (Jeffrey, 
Halliday et al. 2000; Cunningham, Deacon et al. 2003; Fuhrmann, Mitteregger et al. 2007). 
This suggests a possible pathological scenario in which abnormal PrP may start to perturb synaptic 
function early, when morphological alterations are not yet evident. Notably, these very early 
modification can be reversed (Mallucci, White et al. 2007). Subsequently, increasing accumulation 
of abnormal PrP would disrupt membrane properties, destabilizing synaptic structure and leading 
to synapse depletion. In this case, a loss of the trophic action of functional synapses would overlap 
with the consequences of the subversion of the physiological, neuroprotective function of PrP (see 
above). 
At the same time, alterations of the neurotransmission system would give rise to early symptoms 
and, later on, to excitotoxic phenomena. For example, the impairment in VGCCs delivery to the 
pre-synaptic membrane induced by abnormal PrP would lead to weakened glutamatergic 
transmission, which is likely responsible for motor and behavioral dysfunctions. On the long term, 
this could also induce compensatory phenomena which may in turn increase VGCC-independent 
glutamate release. This scenario may be further worsened by the concomitant loss of the 
physiological function of PrP, which would result in increased NMDAR function and impaired 
inhibitory GABAergic transmission. All these factors may cooperate synergistically to predispose 
neurons to excitotoxicity. 
The increasing evidence that synapses are privileged targets in prion diseases and that synaptic 
alterations are the earliest pathological events, open up new avenues for early diagnosis and 
treatment.  
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The intrinsic plasticity of these structures is a very appealing property to be targeted, and, indeed, 
synapse loss has been clearly demonstrated to be reversible, at least in the first stages of the 
disease (Mallucci, White et al. 2007). Of course, the possibility to intervene at this level requires a 
full understanding of the specific pathological mechanisms involved.  
The study of synaptic dysfunction in prion diseases is still a relatively young field of research, but is 
well worth pursuing. A deeper understanding of these mechanisms would allow to design specific 
therapeutic strategies aimed at targeting, if not the primary cause of the disease, the key 
contributor, maybe taking advantage of already existing molecules which have been developed to 
target synaptic dysfunction in other diseases. Moreover, identification of early dysfunction would 
allow to recognize the disease before the terminal situation represented by the full blown clinical 
symptoms, at a stage in which rescue is still possible.  
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AIM OF THE WORK 
Compromised synaptic function plays a determinant role in the pathogenesis of prion diseases. 
Understanding the mechanisms of synaptic dysfunction is therefore fundamental for improving 
our understanding of these pathologies and for devising efficient diagnostic and therapeutic 
strategies.  
In the present work, we investigated this aspect by taking advantage of two different murine 
models of genetic prion diseases. 
Fatal familial insomnia (FFI) and a familial form of the Creutzfeldt-Jakob disease (CJD) are clinically 
distinct diseases linked to the same point mutation in the PrP gene, the D178N. The specific 
phenotypes are determined by the M129V polymorphism which is thought to influence D178N PrP 
misfolding, leading to the formation of distinct prion strains with different neurotoxic properties 
(Bouybayoune, Mantovani et al. 2015). Specifically, FFI is characterized by severe sleep alterations, 
autonomic dysfunction and selective neurodegeneration in the thalamus. CJD is a subacute 
encephalopathy characterized by a rapidly progressive dementia, motor abnormalities and a 
diffused spongiform degeneration mostly involving the cortex, the cerebellum and the striatum. 
Fig 11- The D178N mutation Schematic drawing representing the main neuropathological differences between the two possible 
phenotypes of the D1778N mutation in relation to the 129 polymorphism. Note the selective neuronal loss in the thalamus 
caused by the FFI variant D178N/129M (left) and the diffused corticobasal spongiosis associated to the CJD variant D178N/129V 
(right). (from Montagna 2003) 
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Recently generated transgenic mice expressing the murine homologs of these two variants 
(D177N/128M and D177N/128V) have been shown to recapitulate the key features and the 
phenotypic differences seen in humans (Dossena, Imeri et al. 2008; Bouybayoune, Mantovani et 
al. 2015), but very little is known regarding the synaptic effects of the mutations. 
Notably, the mutant PrPs expressed in these mice are not infectious, indicating that the proteins 
possess disease-encoding properties that are independent of their ability to propagate the 
misfolded conformation (Bouybayoune, Mantovani et al. 2015). This feature is particularly suitable 
for our purpose, because it allows to isolate the neurotoxic mechanisms of abnormal PrP from the 
confounding effects of prion replication. 
Several pieces of evidence indicate that PrP may be directly involved in synaptic transmission, and 
this role may be altered in the disease-causing protein. For example, we have recently 
demonstrated that a different PrP mutation affects the trafficking of the protein causing its 
retention in intracellular compartments. Due to its ability to interact with VGCCs, the mutant 
protein impairs the correct delivery of the channels to presynaptic terminals, resulting inefficient 
glutamatergic neurotransmission (Senatore, Restelli et al. 2013). 
Studies from other groups demonstrated that PrP engages functional interactions with other 
proteins that are important for synaptic function, such as glutamate receptors (Khosravani, Zhang 
et al. 2008; Watt, Taylor et al. 2012). 
Given that also the two variants of the D177N PrP are retained intracellularly (Ivanova, Barmada et 
al. 2001; Fioriti, Dossena et al. 2005; Dossena, Imeri et al. 2008; Bouybayoune, Mantovani et al. 
2015), we asked whether a similar mechanism of interaction and retention could apply also to 
glutamate receptors. To answer this question, we performed confocal analyses and 
electrophysiological recordings on primary hippocampal neurons from FFI and CJD mice. We 
aimed at carrying out a detailed study of the interaction of the mutant proteins with AMPA and 
NMDA receptors, and of the effects of these proteins on the postsynaptic components of 
excitatory neurotransmission. Furthermore, we wanted to verify whether the two mutants 
differed in their effects on synaptic function, because the presence of specific alterations may 
account at least in part for the phenotypic heterogeneity seen in these diseases. 
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MATERIALS AND METHODS 
 
REAGENTS 
 
For cell culture, we used Hank’s Balanced Salt Solution (HBSS), Neurobasal-A medium, Minimal 
Essential Medium (MEM), Dulbecco’s modified Eagle’s medium (DMEM) Basal Medium Eagle 
(BME) and B-27 supplement, that were supplied by Invitrogen (GIBCO). Ultraglutamine and 
Penicillin-Streptomicyn (PenStrep) were supplied by Lonza, Glutamax by ThermoFisher, polylysine, 
papain, trypsin, trypsin inhibitors and aphidicolin by Sigma. Fetal bovine serum (FBS) was acquired 
from HyperClone (primary hippocampal neurons) or Sigma (HeLa cells and cerebellar granule 
neurons). 
Transfections were carried out by using Lipofectamine®2000 purchased from Invitrogen. P-EGFP-
C1 plasmid was provided by Clontech. Plasmids encoding WT, D177N/128V (CJD) and 
D177N/128M (FFI) PrP constructs containing a monomerized version of EGFP (enhanced green 
fluorescent protein) inserted after codon 34 of mouse PrP were provided by Roberto Chiesa 
(Mario Negri Institute for Pharmacological Research) and have been described previously 
(Massignan, Biasini et al. 2010). The AMPA receptor cDNA for GluA2 (R, flop) long C-term in 
pCDNA3 vector for expression and the NMDA receptor cDNA for GluN1 in CMV-pRK 7 vector were 
kindly provided by Professor Peter Seeburg (Max-Planck-Institute for Neurological Research, 
Heidelberg, Germany). 
For immunofluorescence, we used phosphate buffered saline (PBS) and goat serum purchased 
from Lonza and Invitrogen (GIBCO) respectively. 
Primary antibodies were supplied by Synaptic System (anti- Bassoon, anti-Shank2, anti-GluA2, anti-
GluN1 and PanAMPA) or Sigma (anti-Tubulin). Secondary antibodies were all purchased from 
Invitrogen (Alexa Fluor). 4-6-diamidino-2-phenylindole (DAPI) was acquired from Invitrogen. 
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All drugs used for electrophysiology and calcium imaging were provided by Tocris, except for Fura-
2 which was obtained by ThermoFisher. Borosilicate glass capillaries were purchased from World 
Precision Instruments. 
Coimmunoprecipitation was performed by using Igepal, protease inhibitor mixture purchased by 
Sigma, IgG-conjugated Dynabeads® supplied by Dynal, and immunoglobulin-free BSA acquired 
from Sigma. Primary anti-PrP antibody 94B4 was donated by Jan Langeveld (Virologie 
Immunologie Moléculaires, UR892, INRA, Jouy-en-Josas, France). Protein quantification was 
carried out by using BCA assay provided by Pierce. 
For Western blot, we used Tween®20 and Tris obtained from VWR International. Primary anti-
GluR1 and anti-GluR2 antibodies were purchased from Synaptic System. Secondary antibodies 
were acquired from GE Healthcare. Nitrocellulose membranes were purchased by BioRad, and 
Chemiluminescent ECL kit was purchased by Amersham Biosciences. 
For toxicity assays we used Hoechst and propidium iodide (PI) acquired from Sigma or the 
CytoTox96® assay from Promega. 
Other chemicals were of the purest grade available from regular commercial sources. 
 
EXPERIMENTAL PROCEDURES 
 
Animals 
Procedures involving animals and their care were conducted in conformity with the institutional 
guidelines at the IRCCS – Mario Negri Institute for Pharmacological Research in compliance with 
national (D.lgs 26/2014; Authorization n. 19/2008-A issued March 6, 2008 by Ministry of Health) 
and international laws and policies (EEC Council Directive 2010/63/UE; the NIH Guide for the Care 
and Use of Laboratory Animals, 2011 edition). They were reviewed and approved by the Mario 
Negri Institute Animal Care and Use Committee that includes ad hoc members for ethical issues, 
and by the Italian Ministry of Health (Decreto nr 212/2016-PR). Animal facilities meet international 
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standards and are regularly checked by a certified veterinarian who is responsible for health 
monitoring, animal welfare supervision, experimental protocols and review of procedures. 
All efforts were made to minimize the number of subject used and their suffering and housed in 
cages with free access to food and water at 22°C and with a 12-hours alternating light/dark cycle. 
We used C57 black 6 (C57BL/6) mouse strain as control animals, whereas mutant neurons and 
tissues were obtained from transgenic mice expressing the D177N/128M and the D177N/128V 
mutations, referred to as Tg(FFI) and Tg(CJD) mice respectively. The production of these mice is 
reported in (Ref. Dossena 2008 and Boubayoune 2015). These animals are maintained on a 
C57BL/6J/Prnp0/0 (PrP knock-out) background, therefore they express transgenic but not 
endogenous wild-type PrP. 
Cell cultures 
Primary hippocampal neurons were obtained from 2-4-days old pups. 
Animals were sacrificed and hippocampi were isolated under surgical stereomicroscope.  
Separated tissues were digested with Papain (200 U/ml) in CNDM medium (5.8 mM MgCl2, 0.5 
mM CaCl2, 3.2 mM HEPES, 0.2 mM NaOH, 30 mM K2SO4 and 90 mM Na2SO4. pH 7.4, 292 mOsm) 
supplemented with 0.4% glucose for 30 min at 34°C. Enzymatic activity was subsequently blocked 
by incubating the tissue with tripsin inhibitors (10 μg/ml) in CNDM plus 0.4% glucose for 45 min at 
room temperature (RT). Dissociation was performed in MEM supplemented with 10% FBS and 
0.4% glucose. Cells were then spinned down at 1500 rpm for 2 min, resuspended in MEM with 
10% FBS, 0.4% glucose and PenStrep (100 U/ml) and plated on polylisine-coated 18 or 24 mm 
round coverslips. The total number of plated cells was adjusted to 130.000 and 260.000 per each 
18 mm and 24 mm coverslip, respectively. Culture medium was prepared by adding B-27 
supplement (2%), PenStrep (100U/ml) and glutamine (200 mM) to Neurobasal-A. Medium was 
changed after 7 days in culture. 
Cerebellar granule neurons were obtained from 6 days old pups. Cerebella were dissected, sliced 
into ∼1-mm pieces and incubated in HBSS containing 0.3 mg/ml trypsin at 37 °C for 15 min. 
Trypsin inhibitor was added to a final concentration of 0.5 mg/ml, and the tissue was mechanically 
dissociated. Cells were plated at 350–400,000 cells/cm2 on polylysine-coated coverslips. Cells were 
maintained in BME supplemented with 10% FBS, PenStrep (100U/ml), and KCl 25 mM. To reduce 
54 
 
the number of non-neuronal cells, aphidicolin (3.3 μg/ml) was added to the medium 36 h after 
plating. Medium was replaced every 2 days. 
HeLa cells were grown in a 1:1 mixture of DMEM plus Glutamax and αMEM plus Glutamax, 
supplemented with 10% FBS, nonessential aminoacids and PenStrep, and maintained at 37°C in an 
atmosphere of 5% CO2, 95% air. When cells reached 90% confluence in 75-cm2 flask, they were 
split by trypsinization. Medium was removed and after washing in PBS, cells were incubated with 
1.5 ml of trypsin/EDTA solution for 3 minutes at 37°C. Trypsin was inhibited by adding 10 ml of 
complete medium, and the cell suspension transferred in a 15 ml sterile tube and centrifuged at 
900 rpm for 5 minutes. The cell pellet was re suspended in fresh medium and the cell suspension 
was diluted and seeded in 75-cm2 flasks.  
All cells were maintained at 37 °C in an atmosphere of 5% CO2, 95% air. 
Transfection 
For dendritic spine analysis, primary neurons were transfected at days in vitro (DIV) 11-DIV 13 with 
GFP-expressing plasmids. 
For each coverslip, 0.5 µg of DNA were combined with 2.5 µl of Lipofectamine to a final volume of 
90 µl in Neurobasal-A medium, and the mix was incubated for 20 minutes at RT. Culture medium 
was removed from neurons and 210 µl of Neurobasal-A were added to each coverslip. DNA-
lipofectamine complexes were then applied to neurons in a total transfection volume of 300 µl, 
and cells were incubated for 30 minutes at 37°C. Transfection medium was eventually replaced 
with the old culture medium. 
For AMPA and NMDA receptors localization analysis HeLa cells were co-transfected with either WT 
or mutant PrP and GluA2 or GluN1. 
HeLa cells were transfected with the cDNA combinations stated above using the ratio PrP-EGFP 
(WT or FFI or CJD): GluA2 or GluN1 = 0.06: 0.47.  Transfection was performed with Lipofectamine 
according to the manufacturer’s instructions. Briefly, 0.25 μg DNA and 0.5 μl Lipofectamine were 
used to prepare the DNA-lipid complexes in 8-well micro-slides (Ibidi). Cells suspended in culture 
medium were subsequently added at a density of 20.000 cells per well. Following transfection, the 
AMPAR antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) or the NMDAR antagonist 2-
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amino-5-phosphonopentanoate (AP5) were added to the medium to prevent glutamate-induced 
excitotoxicity. 
Immunofluorescence staining 
Neurons were used for immunofluorescent staining on DIV 13-DIV15. 
First, cells were fixed in paraformaldehyde 4% for 8 minutes and washed in PBS twice for 10 
minutes. 
Then, they were washed 3 times for 5 min in low salt and high salt buffer, and incubated for 30 
minutes in goat serum dilution buffer (GSDB) for blocking non-specific reactivity and for 
permeabilization. Primary antibodies were diluted in GSDB, incubated with cells for 2 hours at RT 
and used at the following concentrations: anti-Bassoon (guinea pig) 1:300; anti-Shank2 (rabbit) 
1:500; anti-Tubulin (rabbit) 1:200. 
Afterwards, coverslips were washed in high salt buffer 3 times for 10 minutes and incubated with 
the corresponding secondary antibodies diluted 1:200 in GSDB for 45 minutes at RT. 
Coverslips were washed again 3 times for 5 minutes first in high salt buffer, then in low salt buffer 
and one last time in phosphate buffer and eventually mounted onto slide glasses with Mowiol® 
mounting solution. 
For staining of surface AMPARs, living neurons were incubated with a monoclonal antibody 
directed against the extracellular portion of the receptors (PanAMPA, mouse, 1:100) dissolved in 
Krebs-Ringers-Henseleit solution (KRH, see below) for 5 min at 37°C and washed 3 times with fresh 
KRH. Cells were subsequently fixed and stained as described above. 
Immunofluorescence staining of HeLa cells was performed 48 h after transfection.  
Cells were washed in PBS and fixed with 200 mM Hepes/NaOH pH 7.4 for 10 minutes at RT. After 
washing with PBS and incubation in blocking solution (50mN NH4Cl, 1% bovine serum albumine, 
10% FBS and 0.1% saponin in PBS pH 7.4 for AMPA receptors or 5% FBS, 0.2% bovine serum 
albumine and 0.2% TritonX-100 in PBS pH 7.4 for NMDA receptors) cells were incubated for 1 hour 
at RT or overnight at 4°C with the primary antibody. Anti-GluA2 (rabbit, 1:500) and anti-GluN1 
(mouse monoclonal, 1:1000) were used. 
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After three washing steps in PBS and incubation secondary antibodies (1:500) for 1 hour at RT, 
nuclei were stained by exposing cells to 300 nM (DAPI) in PBS for 10 min at RT. 
Confocal microscopy 
Morphological analyses of primary neurons and HeLa cells were performed on an Olympus FV1000 
confocal microscope equipped with 458, 488 and 515 nm Argon lasers and 405, 559, 594 and 635 
diode lasers, and the associated software FV10-ASW. 
For dendritic spines analysis images of proximal dendrites were acquired with a 60X oil immersion 
objective using a scan format of 1024x1024 pixels. 
Each image consisted of a stack of images taken through the z-plane of the cell. Microscope 
settings were kept constant in each experiment. 
Spines were manually classified with the NeuronStudio software, and density was calculated as 
number of spines/μm. 
The analysis of synaptic markers was carried out on single plan images using ImageJ software 
(National Institute of Health, USA).  Pixel size was 115 nm x 115 nm. The minimum puncta size was 
set to 3 pixels (0.034 μm2). Colocalization of two selected markers was measured using the 
Boolean function “and” for the selected channels. The resulting image was binarized and used as a 
colocalization mask to be subtracted to single channels. The number of puncta resulting from 
colocalization mask subtraction were calculated for each marker. A colocalization fraction was set 
as colocalizing puncta/total puncta number. 
The analysis of synaptic density was performed on clusters lying along dendritic branches. Density 
was calculated as the number of either single channel or colocalizing puncta/μm. 
Coimmunoprecipitation 
For coimmunoprecipitation (co-IP) from hippocampus, the tissue was homogenized in ice-cold co-
IP buffer (75 mM NaCl, 1% Igepal, protease inhibitor mixture, 50 mM Tris-Cl, pH 7.4). After 
centrifugation at 1000 x g for 5 minutes, the supernatant was recovered and protein content 
quantified by BCA assay. 500 μg of protein was diluted in 1 ml of co-IP buffer and after five 
passages through a 23-gauge needle and incubation at 4°C for 30 minutes on a rotating wheel, the 
sample was centrifuged at 1000 x g for 3 minutes to remove the non-soluble material. The 
supernatant was transferred into a new tube and incubated for 1 hour at RT with 20 μl of anti-
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mouse IgG-conjugated Dynabeads. The lysates were then incubated overnight at 4°C with 25 μl/ml 
of anti-mouse IgG-conjugated Dynabeads coated with the primary antibody anti-PrP 94B4. Primary 
antibody (1.5 μg) was incubated with 25 μl of anti-mouse IgG-conjugated Dynabeads for 2 hours at 
RT in PBS plus 0.1% immunoglobulin-free BSA. After three washes with 150 mM NaCl, 0.5% Igepal, 
50 mM Tris-Cl, pH 7.4, immunoprecipitated proteins were eluted by 20 μl DTT-containing Laemmli 
sample buffer and analyzed by Western blot.  
Western blot 
30 or 50 μg of proteins were separated on standard 10-15% SDS-PAGE. For Western blotting, gels 
transferred to nitrocellulose filters were first blocked for 1 h with 5% nonfat dry milk in PBS, and 
then incubated over night with the primary antibodies diluted in PBS with 5% nonfat dry milk 
(1:1000 for anti-GluR1 and anti-GluR2, 1:2500 for anti-PrP 94B4) washed  three folds for 10 
minutes in Phosphate Buffered Saline with Tween (PBST), incubated for 1 hour with the 
peroxidase-conjugated anti-rabbit secondary antibody (1:5000), washed again in PBST as 
described above and once in PBS. Photographic development was by chemiluminescence. Western 
blot bands were quantified by the ImageJ program. 
Toxicity assay 
For toxicity assessment cultures were exposed to the excitotoxic agents for 24 hours. Following 
the stimulation period cell death was determined either with the DAPI/PI method or by measuring 
lactate dehydrogenase release (LDH). 
For DAPI/PI staining cells were incubated with with Hoechst (10 μg/ml) and PI (2 μg/ml) for 30 min 
and mortality was calculated as PI/Hoechst positive nuclei. 
To measure LDH release, the CytoTox96® kit was used according to the manufacturer’s 
instructions. 
Electrophysiology 
Voltage-clamp whole cell recordings were obtained from cultured neurons on DIV 13-DIV16 under 
visual guidance using fluorescence and transmitted light illumination.  
Extracellular solution (KRH) contained 125 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 
25 mM HEPES sodium salt, 2 mM CaCl2 and 6 mM glucose. 
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For standard miniature excitatory postsynaptic currents (mEPSCs) recordings, patch pipettes (2.5-
4.5 MΩ resistance) made from borosilicate glass were filled with a potassium gluconate-based 
solution containing 10 mM KCl, 2 mM MgCl2, 10 mM HEPES sodium salt, 130 mM potassium 
gluconate, 1 mM ethylene glycol tetraacetic acid (EGTA), 4 mM Mg-ATP and 0.3 mM Tris-GTP. For 
rectification index experiments we used cesium gluconate-based solution containing 130 mM 
CsOH, 8 mM CsCl, 2 mM NaCl, 10 mM HEPES sodium salt, 4 mM EGTA, 4 mM Mg-ATP and 0.3 mM 
Tris-GTP and 120 μM spermine.  
Synaptic AMPA receptor-mediated currents were measured by holding neurons at a membrane 
potential of -70 mV in the presence of 1 µM tetrodotoxin (TTX) to block action potentials, 20 µM 
bicuculline and 20 µM AP5 to block GABA and NMDA receptors respectively. 
Rectification experiments were carried out in extracellular solution containing TTX 10 nM, 
bicuculline 20 µM and AP5 100 µM. AMPAR-mediated responses were first recorded at -70 mV 
and then at +50 mV. 
To measure NMDAR-mediated currents, cells were kept in Mg2+ -free KRH in the presence of 1 μM 
TTX, 20 µM bicuculline, 10 μM 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione 
(NBQX), 1 μM strychnine and 20 mM glycine. 200 mM NMDA was applied locally using a Perfusion 
Fast-Step System SF-77B (Warner Instruments, Hamden CT, USA) during 5 sec and then washed. 
Recordings were performed at RT in voltage clamp mode using an Axopatch 200b or a Multiclamp 
700B amplifier (Molecular devices) and pClamp-10 software (Axon Instruments). Series resistance 
ranged from 5 to 20 MΩ and was monitored for consistency during recordings. Cells with leak 
currents >200 pA, Vm> -40 mV and mEPSCs frequency < 0.2 Hz were excluded from the analysis. 
Signals were amplified, sampled at 10 kHz and filtered to 4 KHz, and acquired using pClamp 10 
data acquisition program.  
Analyses were carried out using Clampfit-10.6 software. Traces were lowpass filtered at 1 KHz. 
mEPSCs amplitude and frequency were automatically calculated, and rectification index was 
determined as the ratio of current amplitude at +40 mV and -70 mV. 
Whole-cell NMDA currents were calculated as the maximum peak of the current divided by cell 
capacitance (current density). 
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Calcium Imaging 
 Hippocampal neurons of 13-16 DIV were loaded with 5 μM Fura-2 pentacetoxymethylester in 
culture medium for 45 min at 37 °C, washed in the KRH and transferred to the recording chamber 
of an inverted microscope (Axiovert 100; Zeiss, Oberkochen, Germany) equipped with a 
Polychrome IV (TILL Photonics, Germany). After excitation at 340 and 380 nm, the emitted light 
was acquired in selected regions of interest (ROI) corresponding to neuronal somata at 505 nm at 
1-2 Hz. The exposure time was set at 10 msec for 340 nm and 20 msec for 380 nm. A constant 
value corresponding to the emitted light at 340 nm excitation in the empty area of the coverslip 
was subtracted as a background. After a period for baseline acquisition, neurons were stimulated 
with 30 µM AMPA for 30 sec in the presence of 1 μM TTX, 1 μM Cd2+,100 μM AP5 and 20 μM 
nifedipine, or 50 mM KCl in the presence of 1 μM TTX and 100 μM AP5. 
Statistical analysis 
Statistical analyses were carried out using Excel (Microsoft, Redmond, WA, USA) or PRISM 5 
software (GraphPad, Software Inc.). After testing whether data were normally distributed or not, 
the appropriate statistical tests were used (see figure legends). Data are presented as mean ± 
standard error of the mean (s.e.m.) from the indicated number of elements analysed. The 
differences were considered to be significant if P<0.05 and are indicated by an asterisk; those at 
P<0.01 are indicated by double asterisks; those at P<0.001 are indicated by triple asterisks. 
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RESULTS 
 
Mutant PrP impairs membrane delivery of the GluA2 subunit of AMPA receptors  
Deregulation of excitatory neurotransmission is a common and early hallmark of many 
neurodegenerative disorders, including prion diseases (Mallucci 2009; Miladinovic, Nashed et al. 
2015). AMPA receptors are central elements of the excitatory synapse, as they mediate the 
majority of fast excitation in the CNS. It follows that alterations in their function or trafficking can 
be crucial in the pathogenesis of such conditions.  
PrP was described to interact with AMPARs, and some evidence suggests that this interaction may 
influence the surface expression of the receptors (Watt, Taylor et al. 2012). 
On these bases, we aimed at studying the relationship between AMPARs and two mutant forms of 
prion protein, the D177N/128V and the D177N/128M, linked to CJD and FFI, respectively. 
First, we wanted to verify whether PrP mutations affected the ability of the protein to interact 
with the receptor. To this purpose, we performed coimmunoprecipitation on hippocampal 
homogenates of wild type, CJD and FFI mice of PrP and the two main subunits expressed at 
hippocampal synapses, GluA1 and GluA2 (Schwenk, Baehrens et al. 2014). As shown in fig. 12A, we 
observed that both the wild type and the mutant isoforms of the protein selectively interacted 
with the GluA2 but not with the GluA1 subunit. 
Given that several mutations in the PRNP gene, including the two under investigation in this study, 
were shown to cause intracellular retention of the protein (Ivanova, Barmada et al. 2001; Fioriti, 
Dossena et al. 2005), and since previous work of our group demonstrated that the interaction of 
the mutant protein with the α2δ-1 subunit of the voltage-gated calcium channels (VGCCs) impairs 
the membrane delivery of the receptor complex (Senatore, Restelli et al. 2013), we aimed to 
define whether a similar mechanism of retention could also apply to AMPARs. 
To this end, we investigated the effect of our mutants on the cellular localization of GluA2. We co-
transfected HeLa cells with plasmids encoding for either the wild type or the mutant PrP and 
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GluA2, and we analyzed the localization of the two proteins by confocal microscopy after 
immunofluorescent staining. Consistent with previous studies protein (Ivanova, Barmada et al. 
2001; Fioriti, Dossena et al. 2005), most wild type PrP localized at the cell surface, whereas both 
the mutant isoforms were predominantly found in intracellular compartments. As for GluA2, we 
observed that it was efficiently expressed at the plasma membrane only in cells expressing WT 
PrP, whereas in CJD and FFI PrP-expressing cells most GluA2 signal localized intracellularly (fig. 
12B).                              
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These results indicate that PrP is involved in the trafficking of GluA2, and that this trafficking is 
impaired in the presence of both variants of the D177N mutation. 
Mutant PrPs induce alterations in dendritic spines 
Transgenic CJD and FFI mice have been described to efficiently recapitulate the corresponding 
human diseases (Dossena, Imeri et al. 2008; Bouybayoune, Mantovani et al. 2015). Nevertheless, a 
systematic study of the structure and function of the excitatory synapses was never performed so 
far.  
It has been suggested that synaptic dysfunction and dendritic spine loss may have a central role in 
the pathogenesis of prion diseases (Jeffrey, Halliday et al. 2000; Cunningham, Deacon et al. 2003; 
Fuhrmann, Mitteregger et al. 2007). Moreover, impairment in a mechanism of primary importance 
for synaptic function such as AMPARs trafficking is expected to result in synaptic alterations 
(Hanley 2008; Bassani, Folci et al. 2013). For these reasons, we carried out a detailed synaptic 
analysis of CJD and FFI neurons. 
Dendritic spines are the main sites at which excitatory neurotransmission takes place, and 
modifications in their number and shape has been described in several neurodegenerative 
disorders (Fiala, Spacek et al. 2002; Maiti, Manna et al. 2015). To verify whether mutant PrP 
affected spine morphology, we transfected WT and transgenic primary hippocampal neurons with 
GFP, which served as a cell-filler (fig. 13A). Spine morphological analysis was carried out in mature 
cultures at 14 DIV. 
We calculated the overall spine density (number of spines/dendrite µm) associated to the two 
genotypes, and compared it to that of control neurons. As shown in fig. 13B, a significant 
reduction in spine density was present in both FFI and CJD neurons. 
Next, we performed a detailed analysis of spine morphology. We classified spines into four general 
categories: mushroom, stubby, thin and “other” spines. Spine quantitation shown in fig. 13C 
revealed that in both the genotypes there was a significant reduction in mushroom spines, 
accompanied by a parallel increase in thin spines. 
Figure 12- Mutant PrP interacts with the GluA2 subunit and impairs its membrane delivery. (A) Co-immunoprecipitation of PrP 
and GluA1 or GluA2 from hippocampal protein extracts of WT, FFI and CJD mice. The image is representative of 3 independent 
experiments. (B) Co-expression of WT (upper row) or mutant (central and lower rows) PrP and GluA2 in HeLa cells. 
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These data indicate that the expression mutant PrP is associated to a defective dendritic spine 
development, characterized by a reduction in the overall number of protrusions and a 
morphological conversion from a more mature, mushroom-rich phenotype to a more immature, 
thin-rich phenotype. 
Figure 13- Neurons expressing mutant PrP show reduced dendritic spine density and altered spine morphology. (A) Confocal 
images of GFP-transfected primary hippocampal neurons from WT or transgenic mice. Scale bar: 5 μm. (B) Quantitative analysis 
of total spine density (spines/μm). (C) Quantitative analysis of mushroom, thin, stubby and atypical spines. Spine percentage was 
calculated as the number of spines of a given class divided by the total number of spines per field. All values are mean ± s.e.m. 
Statistical test: Kruskal-Wallis test followed by Dunn’s correction for multiple comparisons. ***P< 0.001. n= 4 independent 
experiments. 
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CJD and FFI mutations differently impact functional synapses 
Although most excitatory synapses are formed on dendritic spines, these two elements cannot be 
strictly assimilated to one another, because functional excitatory synapses can also form outside 
spines, for example directly on the dendritic shaft (Aoto, Ting et al. 2007). On the other hand, 
although characteristic mature spines are normally considered to be mushroom-shaped, synaptic 
contacts may sometimes develop also at the level of filopodial protrusions (Menna, Zambetti et al. 
2013). Therefore, a caveat must be kept in mind when drawing conclusions about the functional 
state of synapses from dendritic spines. 
Accordingly, we aimed at deepening the synaptic characterization of CJD and FFI neurons through 
more specific structural and functional analyses. 
First, to uncover possible differences in the overall number of receptors at the synapse we stained 
neurons for surface AMPARs and we calculated the density of the clusters (number of AMPAR 
puncta/μm, fig. 14B). A significant reduction in the number of postsynaptic sites was observed in 
CJD neurons. A similar trend, although not statistically significant, was present also in FFI cells. 
Next, we wanted to determine how many postsynaptic sites were coupled to presynaptic 
terminals to form bona fide synaptic contacts. To this purpose, we stained neurons for Bassoon 
and Shank2 as pre- and postsynaptic markers, respectively. We performed a colocalization analysis 
and we calculated the fraction of postsynaptic puncta colocalizing with presynaptic terminals 
(number of Shank2-Bassoon colocalizing puncta/total number of Shank2 puncta or number of 
colocalizing puncta/total number of Bassoon puncta). As shown in fig. 14C and D, the fractional 
colocalization was lower in both CJD and FFI neurons compared to the controls, suggesting that 
both PrP mutations negatively impact the formation of structurally mature synapses. The effect 
did not vary when the number of colocalizing puncta was compared to either the pre- or the 
postsynaptic marker (fig 14D), arguing against the presence of mutation-specific effects on the 
overall amount of Shank and Bassoon. 
65 
 
 
Figure 14- Neurons expressing mutant PrP show abnormal synaptic structure. (A) Immunocytochemical staining for surface 
AMPARs (green) and tubulin (red) in WT and transgenic neurons. Scale bar: 10 μm. (B) Quantitative analysis of surface AMPAR 
density (AMPAR puncta/μm). Statistical test: one-way ANOVA followed by Bonferroni correction for multiple comparisons. (C) 
Immunocytochemical staining for bassoon (green) and shank2 (red). Scale bar: 5 μm. (D) Quantitative analysis of pre- to post-
synaptic colocalization. Fractional colocalization is calculated as the number of colocalizing pre- and post-synaptic puncta divided 
by the total number of shank2 puncta (upper panel) or bassoon puncta (lower panel). Statistical test: Kruskal-Wallis test 
followed by Dunn’s correction for multiple comparisons. All values are mean ± s.e.m. **P< 0.01, *P< 0.05. n= 4 independent 
experiments. 
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Conversely, electrophysiological recordings of AMPAR-mediated mEPSCs shown in fig. 15 revealed 
a clear difference between the two mutations.  
In particular, CJD neurons displayed a significant decrease in mEPSCs frequency, in line with a 
genuine reduction in the number of functional synapses. In parallel, we observed an increase in 
the amplitude of the events which might be attributable to either an increased strength of the 
residual postsynaptic sites or a modification in the conductance of the receptors. 
In contrast, FFI neurons fully compensated for the structural defects, as both the frequency and 
the amplitude of mEPSCs were undistinguishable from those recorded in WT neurons. 
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Figure 15- Altered synaptic function in CJD but not in FFI neurons. (A) Representative traces of mEPSCs. (B) Mean mEPSCs 
frequency in the different genotypes. (C) Cumulative mEPSCs amplitude histogram for WT and transgenic neurons. Inset shows 
the mean mEPSC amplitude. All values are mean ± s.e.m. Statistical test: one-way ANOVA followed by Bonferroni correction for 
multiple comparisons.  ***P< 0.001, **P< 0.01, *P< 0.05. n= 9 independent experiments. 
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Taken together, these results suggest that although both the mutants show similar structural 
alterations, the CJD mutation seems to have a more prominent functional impact, whereas FFI 
neurons have a more preserved synaptic function. 
AMPA receptors trafficking is altered in CJD but not in FFI neurons  
Glutamate receptor levels at the synapse are very dynamic, and their ability to move in and out 
the postsynaptic plasma membrane is crucial for the modulation of synaptic transmission. 
Trafficking of these proteins is, in fact, a key process which not only depends on, but also 
determines the structural and functional integrity of the synapses (Hanley 2008).  
Data obtained so far demonstrated that mutant PrP causes mislocalization of GluA2 and loss of 
dendritic spines and functional synapses. This could be consistent with an impaired glutamate 
receptors homeostasis.  
We aimed, therefore, to explore the possibility that mutant PrP affected AMPARs trafficking, and 
we used the induction of synaptic plasticity as a method for assessing the neuronal ability to 
deliver AMPA receptors to the plasma membrane. In particular, we focused our attention on 
synaptic scaling. 
Synaptic scaling is a homeostatic form of plasticity that is triggered by global decreases or 
increases in the network activity. Such changes elicit a compensatory response of opposite sign, by 
which neurons scale up or down the strength of all the synapses to normalize their output without 
changing the relative strength of synaptic inputs. This allows to maintain neuronal responsivity 
within an optimal working range, without disrupting information storage or processing 
mechanisms that rely on differences in synaptic weights (Turrigiano 2008). Like most of the other 
forms of plasticity, synaptic scaling is achieved through both pre- and postsynaptic adjustments 
(Pozo and Goda 2010). At a postsynaptic level, it depends on the accumulation or removal of 
AMPA receptors. 
A widely-established protocol for inducing synaptic scaling consists of blocking neuronal firing over 
several hours to induce a scaling-up of synaptic strength. Accordingly, we treated mature cultures 
at DIV 13-14 with 1 μM TTX and we analyzed them 48 hours later. 
Electrophysiological recordings showed that WT neurons underwent a significant increase in 
synaptic strength upon TTX treatment, as demonstrated by a concomitant increase in both 
69 
 
mEPSCs amplitude and frequency. FFI neurons also displayed a strong postsynaptic potentiation, 
which appeared in the form of increased mEPSCs amplitude which was not paralleled by an 
increase in frequency. Conversely, CJD neurons showed no response to TTX treatment, arguing for 
the presence of a significant defect in AMPARs trafficking (fig 16A and B). 
We next examined the TTX-induced AMPARs clustering to determine whether the functional 
discrepancies that we observed in FFI and CJD neurons could in fact be ascribable to differential 
effects of the mutations on receptors trafficking. To this purpose, we stained control and TTX-
treated neurons for surface AMPARs and for the presynaptic marker Bassoon, and we performed a 
colocalization analysis (see above). This allowed us to consider only the synaptic fraction of AMPA 
receptors. In line with the functional data, the experiments shown in fig. 16C and D revealed that 
the TTX- induced increase in synaptic clustering of the receptors occurred in WT and FFI neurons, 
but was impaired in the presence of the CJD mutation. 
70 
 
 
Figure 16- Synaptic scaling is impaired in CJD but not in FFI neurons. (A) Representative mEPSCs traces before (upper traces) 
and after (lower traces) the induction of synaptic scaling in the different genotypes. (B) Mean mEPSCs amplitude and frequency 
in control conditions and after 48 hours-treatment with 1 μM TTX in WT, FFI and CJD neurons (left, central and right pair of 
graphs, respectively). Statistical test: unpaired Student’s t-test. n= 4 independent experiments. (C) Representative images of WT 
or mutant dendrites showing the colocalization between bassoon (blue) and surface AMPARs (red) before (left panels) and after 
(right panels) the induction of synaptic scaling. Scale bar: 5 μm. (D) Quantitative analysis of pre- to postsynaptic colocalization in 
control conditions or after TTX treatment. Fractional colocalization is calculated as the number of colocalizing bassoon and 
AMPAR puncta divided by the total number of bassoon puncta. Statistical test: one-way ANOVA followed by Bonferroni 
correction for multiple comparisons. All values are mean ± s.e.m.**P< 0.01, *P< 0.05. 
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Once again, these results confirmed that CJD and FFI mutations have a different impact on the 
function of excitatory synapses. In particular, CJD PrP seems to have a greater effect on AMPARs 
trafficking compared to the FFI variant. Notably, however, none of the mutant genotypes showed 
an increase in mEPSCs frequency following TTX treatment. This suggests the occurrence of 
additional defects, possibly involving the presynaptic compartment. 
Impaired trafficking of AMPA receptors specifically involves the GluA2 subunit and results in 
exposure of GluA2-lacking receptors in different types of genetic prion diseases  
After having demonstrated that mutant PrP, and especially the CJD variant, was associated to a 
defective trafficking of AMPA receptors we aimed to verify whether this impairment selectively 
affected the GluA2-containing receptors. 
A reasonable hypothesis was, in fact, that the mutant PrP-dependent intracellular retention of 
GluA2 resulted in a rearrangement in the subunit composition of the remaining receptors. 
To examine the GluA2 content of synaptic AMPARs in the different genotypes we measured the 
rectification index of AMPAR-mediated miniature currents. 
The current-voltage relationship (I/V) of AMPA receptors is largely determined by the GluA2 
subunit. GluA2-containing receptors show a linear I/V relationship, whereas GluA2-lacking 
receptors are inwardly rectifying; in other words, they conduct little outward current at positive 
potentials (fig. 17). It follows that the ratio between mEPSCs amplitude calculated at positive and 
negative potentials (we chose +50 and -70 mV, respectively), which is referred to as rectification 
index, will be close to 1 for GluA2-containing receptors, and lower for GluA2-lacking receptors.  
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The analysis of the rectification index shown in fig. 18B revealed that CJD neurons displayed a 
significantly lower ratio compared to the controls, arguing for the presence of an increased 
synaptic population of GluA2-lacking AMPARs. A similar trend, although not statistically significant, 
was observed for FFI neurons. 
GluA2 is a critical subunit in determining many of the major biophysical properties of AMPA 
receptors, including calcium permeability (Isaac, Ashby et al. 2007). In particular, GluA2-containing 
receptors are only permeable to sodium and potassium, whereas GluA2-lacking receptors are also 
permeable to calcium.  
To verify whether the higher expression of GluA2-lacking AMPARs in CJD neurons resulted in 
increased neuronal calcium permeability, we measured the intracellular calcium levels following 
AMPA receptors activation. AMPA was administered to Fura-2-labeled WT and CJD neurons, and 
calcium imaging was performed in the presence of the NMDAR blocker AP5, the general VGCCs 
blocker cadmium and the L-type calcium channel inhibitor nifedipine, to isolate the AMPAR-
mediated component. As shown in fig. 18D, the peak calcium increase in CJD neurons was greater 
Figure 17- Representative I-V curves for AMPA receptors. Current- voltage plots for GluA2-containing (upper panel) and GluA2-
lacking (lower panel) AMPA receptors. The solid line is obtained by plotting EPSC amplitude as a function of holding potential. 
Note that current-voltage relationship deviates from linearity at positive potentials in case of GluA2-lacking receptors. This 
behavior is due to the inwardly rectifying properties of these receptors, which have a reduced outward conductance with 
respect to the GluA1-containing receptors. Modified from Billa et al., 2010. 
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than in WT neurons, confirming our hypothesis. Fig. 18C shows the mean responses in two 
independent experiments. 
Excessive activity-dependent calcium influx is a key mediator of excitotoxicity (Arundine and 
Tymianski 2003). Interestingly, an increasing body of literature demonstrates that upregulation of 
calcium permeable AMPARs (CP-AMPARs) occurs in different pathological conditions, and calcium 
entry through these receptors can directly trigger neuronal death (Brorson, Manzolillo et al. 1994; 
Liu and Zukin 2007). Therefore, activation of CP-AMPARs can play a major role in excitotoxic 
processes. 
To verify whether the mutant PrP-dependent increase in CP-AMPARs resulted in enhanced 
susceptibility to excitotoxicity, we exposed neurons to AMPA for 24 hours and we measured cell 
death through dual DAPI/PI staining. Preliminary data shown in fig. 18E indicated that, indeed, CJD 
neurons displayed an increased sensitivity to AMPA toxicity compared to the controls. Surprisingly, 
a similar effect was observed also in FFI neurons, suggesting that increased expression of GluA2-
lacking AMPARs may be a common hallmark of the two mutations. 
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Figure 18- Mutant neurons display increased exposure of GluA2-lacking AMPARs, increased AMPA-induced calcium 
permeability and enhanced susceptibility to excitotoxic cell death. (A) Representative mEPSCs at +50 (top) and -70 (bottom) 
mV in the different genotypes. (B) Rectification index values for WT, CJD and FFI neurons. Statistical test: Mann-Whitney t-test 
for WT vs CJD; unpaired Student’s t-test for WT vs FFI. n= 3 independent experiments. (C) Representative traces of intracellular 
calcium levels (normalized fluorescence 340 nm/fluorescence 380 nm in Fura-2-treated cells) in WT (black) and CJD (red) 
neurons stimulated with AMPA (30μM for 30 sec).  (D) Quantification of AMPA-induced calcium peaks in WT and CJD neurons. 
Statistical test: unpaired Student’s t-test. n= 2 independent experiments. (E) Normalized cell death (PI puncta/Hoechst puncta) 
for CJD (left) and FFI (right) neurons compared to WT. Statistical test: unpaired Student’s t-test. All values are mean ± s.e.m. 
***P< 0.001, **P< 0.01, *P< 0.05. 
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Given the relevance of increased expression of CP-AMPARs in a neurodegenerative context, we 
investigated whether this mechanism was shared by other PrP mutations.  
Unpublished data of our group indicate that interaction and retention of GluA2 also occurs in the 
presence of PG14 mutation. PG14 PrP contains a nine-octapeptide insertion (fig. 19) and in 
humans is associated to a neurological disease characterized by progressive dementia and ataxia. 
In 2000, Chiesa et al. reported that mice expressing the murine homolog of the mutation develop 
a fatal neurological disorder characterized by cerebellar atrophy with massive degeneration of 
cerebellar granule neurons (CGNs) (Chiesa, Drisaldi et al. 2000). We therefore performed the same 
set of experiments in CGNs from WT and PG14 mice. 
 
 
 
Once again, we observed that mutant neurons displayed reduced rectification index (fig. 20A and 
B). Calcium imaging experiments revealed a significantly higher AMPA-induced calcium influx in 
PG14 neurons, and the mutant cells maintained elevated intracellular calcium concentrations 10 
minutes after stimulation. Finally, we found that PG14 CGNs were more susceptible to AMPA- but 
not to NMDA-induced cell death than the controls (fig. 20C-F). 
Figure 19- PG14 PrP. Schematic representation of the PG14 allele 
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Taken together, these results suggest that a common pathological mechanism operates in 
different prion diseases, and may therefore represent a useful therapeutic target. 
NMDAR function is differentially affected by CJD and FFI mutations  
Data obtained so far indicated that a substantial difference existed between the two mutant 
genotypes in terms of AMPARs trafficking capacity. This phenomenon, however, hardly depended 
on the direct action of PrP on AMPA receptors, as we had demonstrated that interactions with the 
receptor and retention of GluA2 were similar in CJD and FFI neurons. 
We therefore reasoned that the cause may lay elsewhere, at the level of different pathways not 
directly associated to AMPAR trafficking. 
NMDAR activity is necessary for regulating AMPAR mobility during synaptic development and 
plasticity, and plays a critical role in dendritic spine formation and maintenance (Hanley 2008; 
Sala, Cambianica et al. 2008). Since PrP has been described to interact and regulate also NMDARs 
(Khosravani, Zhang et al. 2008), we hypothesized that differences between the two mutations 
could occur at this level. 
To test this hypothesis, we coimmunoprecipitated PrP and the NMDAR subunits GluN1 and 
GluN2B from hippocampal homogenates of WT and transgenic mice. These experiments, shown in 
fig. 21A, revealed interesting differences. Whereas WT and CJD PrPs interacted with both the 
subunits, FFI PrP showed only a weak association to GluN2B and lost completely its ability to 
interact with GluN1. 
To verify whether this defect could differentially impact the cellular localization of NMDAR, we co-
transfected HeLa cells with either WT or mutant PrP and GluN1. Once again, we observed that the 
Figure 20- PG14 PrP alters AMPAR subunit composition, affecting calcium permeability and susceptibility to excitotoxicity. (A) 
Rectification index values for WT and PG14 PrP-expressing neurons. Statistical test: unpaired Student’s t-test. n= 3 independent 
experiments. (B) Representative mEPSCs at +50 (top) and -70 (bottom) mV in WT and PG14 neurons. (C) Representative traces of 
calcium imaging experiments showing calcium responses to AMPA and KCl in CGNs from WT (left) and PG14 (right) mice. 
Quantification of AMPA-induced calcium peaks (D) and intracellular calcium levels 10 minutes after AMPA stimulation (E) in WT 
and PG14 CGNs. Statistical test: Mann-Whitney t-test. n= 6 independent experiments. (E) Normalized cell death (LDH release) for 
WT (C57) and PG14 CGNs following AMPA (left) and NMDA (right) treatment. Statistical test: unpaired Student’s t-test. n= 3 
independent experiments. All values are mean ± s.e.m. ****P< 0.0001, ***P< 0.001, **P< 0.01, *P< 0.05. 
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localization of the subunit depended on its interaction with PrP. GluN1 was expressed at the 
plasma membrane in the presence of the WT protein, whereas it was intracellularly retained when 
co-expressed with the CJD variant. On the other hand, the subunit was correctly delivered to the 
cell surface in FFI neurons, where the interaction with PrP was lost (fig. 21B). 
To assess the functional significance of our findings, we investigated the expression of functional 
NMDA receptors. Since NMDAR-mediated mEPSCs can be difficult to detect, due to their small 
amplitude which is often close to noise level (Bardoni, Magherini et al. 1998; Townsend, Yoshii et 
al. 2003), we measured whole-cell currents elicited by local application of NMDA. Whole-cell 
currents are large enough to measure, because they result from the activation of all the synaptic 
and nonsynaptic receptors (including somatic receptors) reached by the agonist. Since the 
amplitude of the current depends also on the size of the cell, which affects the absolute number of 
available receptors, we normalized the peak amplitude to the cell capacitance, which provides an 
estimate of cell size, thus allowing to correct for cell dimension. The resulting measure was 
referred to as current density.  
In line with GluN1 localization, we observed that the current density of FFI was comparable to that 
of WT cells, whereas it was significantly decreased in CJD neurons (fig. 21C and D).  
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Figure 21- Differential interactions and functional effects of FFI and CJD PrPs on NMDAR. (A) Co-immunoprecipitation of PrP 
and GluN1 or GluN2B from hippocampal protein extracts of WT, FFI and CJD mice. (B) Co-expression of WT (upper row) or 
mutant (central and lower rows) PrP and GluN1 in HeLa cells. (C) Representative traces of whole-cell currents evoked by 5 sec 
exposure to 200 μM NMDA in the different genotypes. (D) Normalized current density in FFI and CJD neurons compared to the 
controls. Statistical test: unpaired Student’s t-test. n= 4 independent experiments. All values are mean ± s.e.m. *P< 0.05. 
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Given that FFI neurons display normal synaptic scaling, we examined whether preserved NMDAR 
function could contribute to this process. To this purpose we treated WT and FFI neurons with TTX 
(1μM) alone, with TTX together with the NMDAR antagonist AP5 (100 μM), or with AP5 alone, and 
we recorded AMPAR-mediated mEPSCs after 48 h. Preliminary data obtained in WT neurons 
showed that all the treatments produced an increase in the amplitude of mEPSCs in WT neurons 
(fig. 21, left panel), consistent with previous reports (Sutton, Ito et al., 2006). 
Conversely, in FFI neurons (fig. 21, right panel) we observed the increase in mEPSCs amplitude 
only after either TTX or AP5 treatment. Surprisingly, synaptic potentiation did not occur when 
blockade of action potential firing was associated to the suppression of NMDAR activity 
(TTX+AP5). 
This preliminary finding suggests that FFI neurons possess a compensatory mechanism that allows 
the establishment of synaptic scaling in response to chronic blockade of presynaptic firing, which 
requires NMDA receptors activity.   
 
 
 
 
Figure 22- Activity blockade requires NMDAR function to induce synaptic scaling in FFI neurons. Cumulative mEPSCs amplitude 
histogram in control conditions and after 48 hours-treatment with TTX (1 μM), TTX + AP5 (100 μM) and AP5 for WT (left) and FFI 
(right) neurons. Insets show the mean mEPSC amplitude. Statistical test: Kruskal-Wallis test followed by Dunn’s correction for 
multiple comparisons. All values are mean ± s.e.m. ***P< 0.001, **P< 0.01. 
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Taken together, these results indicate that the two variants of the D177N mutation impact 
differently on NMDA receptors. Our data also suggest that preserved NMDAR function may be 
particularly important for the regulation of AMPAR trafficking during synaptic plasticity. We 
therefore speculate that the differential interaction of mutant PrP with NMDAR may explain some 
aspects of the phenotypic heterogeneity observed in these neurons. 
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DISCUSSION 
 
Although the neurodegenerative pathways activated by the abnormal PrP are not known, synaptic 
dysfunctions appear to be a major pathological determinant of prion diseases. 
Synaptic alterations have been described to occur before and independently of neuronal loss 
(Clinton, Forsyth et al. 1993; Jeffrey, Halliday et al. 2000; Ferrer 2002), suggesting that synaptic 
deregulation may be at the origin of the symptomatology, and eventually lead to neuronal death 
due to a combined action of a lack of activity-dependent trophic signals and excitotoxicity 
(Cunningham, Deacon et al. 2003; Chiesa, Piccardo et al. 2005; Bell and Hardingham 2011; 
Senatore, Colleoni et al. 2012). 
Several pieces of evidence indicate that PrP is directly involved in synaptic regulation, and indeed 
pathological mutations of the protein negatively affect this function. For example, our group has 
recently found that mutant PrP is retained in the endoplasmic reticulum where it interacts with 
the VGCCs. This impairs the correct delivery of the channels to the cell surface, impacting 
glutamatergic transmission and leading to the onset of neurological symptoms (Senatore2012). 
However, this phenomenon alone does not account for neurodegeneration. Other studies have 
demonstrated that PrP engages functional interactions with postsynaptic proteins such as AMPA 
and NMDA receptors (Khosravani, Zhang et al. 2008; Watt, Taylor et al. 2012), but the relevance of 
these interactions in prion diseases was never explored so far. 
The aim of the present work was to mark a step forward in linking synaptic dysfunction and 
neurodegeneration in these disorders. We hypothesized that interactions between the 
pathological prion protein and glutamate receptors could result in postsynaptic defects, producing 
adverse effects on neuronal function and survival. 
To verify this, we took advantage of two different models of inherited prion diseases: FFI mice 
which express the D177N/128M mutation, and CJD mice which express the D177N/128V. Both 
variants of the protein accumulate intracellularly (Ivanova, Barmada et al. 2001; Fioriti, Dossena et 
al. 2005; Dossena, Imeri et al. 2008) and have specific neurotoxic properties which are 
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independent of prion replication (Bouybayoune, Mantovani et al. 2015; Chiesa, Restelli et al. 
2016). 
We used primary hippocampal neurons from these mice to characterize the interactions of the 
mutant proteins with AMPA and NMDA receptors, and to analyse the effects of the mutations on 
postsynaptic structure and function. 
We first observed that both the WT and the mutant isoforms of PrP interact with the GluA2 but 
not with the GluA1 subunit of AMPA receptors. This finding contrasts with a previous report which 
showed that the protein interacts with both subunits (Watt, Taylor et al. 2012). The authors also 
showed that the interaction with AMPAR is lost in the presence of pathogenic PrP mutations, 
including the two under investigation in our study, and suggest that functional deficits may arise 
from a loss of interaction of the mutant protein with the receptor. Once again, this contrasts with 
our observation that the interaction with GluA2 is conserved in the presence of the mutations, 
causing the intracellular retention of the subunit.  
The intracellular retention of GluA2 in mutant neurons did not result in a decreased basal 
amplitude of AMPAR-mediated mEPSCs, as would be expected in the presence of a general 
reduction in the number of receptors. This is in line with several studies demonstrating that a lack 
of GluA2 does not affect basal synaptic transmission, because of a compensatory increase in the 
insertion of GluA1 (possibly through formation of homomeric GluA1 receptors) (Meng, Zhang et al. 
2003; Gainey, Hurvitz-Wolff et al. 2009). Consistently, we observed in mutant neurons a lower 
rectification index relative to WT cells, indicative of a high synaptic content of GluA2-lacking 
AMPARs. Our functional data, thus, support the idea that PrP does not interact with GluA1, which 
is free to compensate for the lack of GluA2, at least under basal conditions. Moreover, as 
discussed below, many of the defects that we found in the mutant neurons can be largely 
explained by the presence into the membrane of AMPARs lacking GluA2. We therefore suggest 
that mutant PrP impacts AMPAR trafficking and function due to the selective, intracellular 
retention of GluA2. 
Given the central role of dendritic spines in synaptic transmission, it is not surprising that several 
brain disorders, including neurodegenerative diseases, are associated to alterations in these 
structures. In prion diseases, dendritic spine pathology has been reported as an early 
manifestation of prion infection (Jeffrey, Halliday et al. 2000; Cunningham, Deacon et al. 2003; 
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Fuhrmann, Mitteregger et al. 2007). We found that dendritic spine defects and synaptic 
alterations also occur in vitro, in models of inherited diseases in which neuronal pathology is 
independent of prion replication. These findings endorse the centrality of synaptic pathology in 
these disorders, which is most likely attributable to cell-autonomous mechanisms depending on 
the abnormal PrP. 
When speculating about the nature of these mechanism, it must be considered that spine and 
synapse development are complex processes, regulated at many different levels.  
Relevant to our interests is the notion that a close correlation exists between the size of the spine 
and the density of AMPARs at the synapse. In other words, regulation of spine size is linked to 
regulation of AMPAR number, and AMPAR trafficking has been proposed to be one of the primary 
driving forces in spine morphogenesis (Hanley 2008). In particular, the N-terminal domain of 
GluA2 was identified as a direct modulator of spine morphogenesis, and a decrease in spines and 
functional synapses was observed upon GluA2 knock-down (Passafaro, Nakagawa et al. 2003). 
Although the precise molecular details are still unclear, the mechanism for this effect appears to 
involve an interaction between GluA2 and N-Cadherin, which is important for pre- and 
postsynaptic adhesion (Saglietti, Dequidt et al. 2007). 
The intracellular retention of GluA2 may therefore, at least in part, explain the altered spine 
morphology and the reduced juxtaposition between pre- and postsynaptic terminals observed in 
mutant neurons. However, PrP is also involved in dendritic spine regulation via Fyn kinase (Toni, 
Spisni et al. 2006; Babus, Little et al. 2011; Um, Nygaard et al. 2012; Koleske 2013), and it is likely 
that a subversion of the physiological function of the protein at this level may contribute to the 
phenotype. 
Interestingly, despite the common structural defects of spines and synapses, the two mutations 
show different functional effects. 
CJD neurons display a severe but straightforward phenotype. Basal synaptic transmission is clearly 
impaired in CJD neurons, in line with the reduced number of functional synapses formed. 
Moreover, the lower rectification index is indicative of a reduced content of GluA2-containing 
receptors. This may also explain the increased amplitude of the miniature events, because GluA2-
lacking AMPARs are known to display higher conductance (Isaac, Ashby et al. 2007). However, 
these neurons seem to be unable to compensate for the loss of GluA2 with other subunits upon 
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the induction of synaptic plasticity: the absence of synaptic potentiation in response to TTX 
treatment indicates that the impaired trafficking of GluA2 is paralleled by an overall alteration in 
AMPAR homeostasis. The increased expression of GluA2-lacking receptors, which is linked to 
higher calcium permeability (Isaac, Ashby et al. 2007), is in fact confirmed by the increased 
AMPAR-mediated calcium influx in CJD neurons. Notably, we show that this results in higher 
susceptibility to AMPA toxicity with respect to WT neurons. 
This finding may have relevant clinical implications. Epileptic seizures are, in fact, frequently 
observed in CJD patients (Ng, Westover et al. 2014), and activation of CP-AMPARs in these 
conditions may significantly contribute to excitotoxicity. Our data therefore suggest that targeting 
of CP-AMPARs is a potentially interesting therapeutic option to be explored in CJD.  
Evidence obtained in FFI neurons are more complex to interpret. The surprising finding here is that 
the presence of significant structural alterations does not seem to affect synaptic transmission and 
plasticity. This indicates that other mechanisms of functional compensation are active in these 
neurons.  
For example, rectification index is not significantly reduced in FFI neurons, arguing for the 
presence of a higher proportion of synaptic GluA2-containing AMPARs, with respect to CJD cells. 
Interestingly, it has been reported that FFI PrP tends to be more expressed at the cell surface than 
the CJD variant in CGNs (Fioriti, Dossena et al. 2005). If this were the same in hippocampal 
neurons, lower intracellular retention of the protein might imply lower retention of the interacting 
partners too. In this case, a higher amount of GluA2 would be free to reach the plasma membrane.  
Although controversial, some authors suggested that GluA2 plays a specific role in driving AMPAR 
insertion during synaptic scaling (Gainey, Hurvitz-Wolff et al. 2009; Pozo and Goda 2010). A 
different availability of GluA2 in FFI and CJD neurons may therefore contribute to the differential 
ability to support homeostatic plasticity.  
A lower proportion of GluA2-lacking, CP-AMPARs should also result in lower AMPA-induced 
calcium influx compared to CJD neurons. In perspective, it will be important to verify this 
hypothesis.  
In a way, experiments on PG14 neurons support the idea of a correlation between the amount of 
membrane protein and the severity of the phenotype: Fioriti and colleagues found that surface 
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PrP expression in PG14 neurons was much lower than in FFI (Fioriti, Dossena et al. 2005). In line 
with this observation, we found that PG14 CGNs, like CJD neurons, display a markedly reduced 
rectification index and increased AMPA-induced calcium influx. Importantly, these data also 
suggest that increased expression of CP-AMPARs may be a common pathological mechanism in 
genetic prion diseases. 
However, increased susceptibility to AMPA-induced cell death was observed in all the mutants 
analyzed, including FFI. This is not necessarily in contrast with what was discussed so far, because 
a defect in membrane delivery of GluA2 does exist in FFI neurons, although possibly milder than in 
the other mutants. Increased expression of CP-AMPARs is therefore likely to occur also in this 
case, and may be sufficient to trigger excitotoxicity upon the prolonged and massive activation of 
the receptors elicited in our experimental protocol. 
Notably, PG14 CGNs are more sensitive to AMPA and not to NMDA toxicity. This is the proof of 
concept that increased expression of CP-AMPARs is a specific mechanism of neurodegeneration in 
these mutants.  
Our analysis of the interaction between PrP and NMDARs provides another interesting basis for 
speculating about the mechanisms of functional compensation that operate in FFI neurons. We 
report that, unlike the CJD variant, FFI PrP loses the ability to interact properly with NMDARs. In 
the absence of a physical association, the receptors are not retained intracellularly by the mutant 
protein, and their localization and function are, therefore, unaffected. Preserved NMDAR function 
may, in turn, contribute to support AMPAR trafficking and thus normal synaptic activity. 
Different mechanisms may be involved in a possible NMDA-mediated support of AMPA receptor 
trafficking. For example, SynGAP is a downstream component of NMDAR signaling complex that is 
physically associated to GluN2B-containing receptors and which negatively regulates AMPAR 
trafficking. Activation of NMDARs leads to SynGAP phosphorylation by CaMKII, which reduces its 
negative control on Ras and Rap, two other components of NMDAR signaling pathways involved in 
the regulation of AMPAR trafficking. This results in increased exocytosis and decreased recycling of 
the receptors, thereby promoting AMPAR insertion at the synapse (Jeyabalan and Clement 2016). 
Notably, SynGAP signaling operates also in basal conditions (Wang, Held et al. 2013). It is therefore 
tempting to speculate that NMDAR activity in FFI neurons may compensate via SynGAP for the 
defects in AMPAR trafficking, potentiating the insertion of the receptors which escape PrP 
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retention. Conversely, this mechanism would not be possible in CJD neurons due to a lack of 
functional NMDARs. Experiments are currently being performed to verify this possibility. 
Our last experiments, showing that synaptic potentiation is impaired in FFI neurons when 
blockade of  neuronal firing is associated to inhibition of NMDARs, argue for an NMDAR 
dependence of synaptic scaling in these cells, further upholding the hypothesis that the 
functionality of these receptors provides cells with an important compensatory capacity. It is 
essential to state, though, that these are only preliminary data, and therefore they must be 
considered with caution. 
A role for NMDARs in homeostatic plasticity has been proposed by several authors, although 
findings are controversial and the precise mechanisms involved remain to be elucidated. In 
particular, NMDAR-mediated miniature activity was shown to exert a tonic suppression of local 
protein translation in the dendrites, thereby limiting synthesis and incorporation of AMPARs. 
Blockade of this activity with AP5 results in a rapid scaling-up of synaptic strength (Sutton, Ito et al. 
2006; Wang, Held et al. 2011; Wang, Held et al. 2013). This is consistent with our observations in 
WT neurons, but contrasts with findings in FFI cells, in which synaptic scaling was suppressed in 
the presence of concomitant blockade of neuronal firing and NMDARs. This may suggest that 
mutant neurons develop a compensatory mechanism which shifts NMDAR spontaneous activity 
from repressing to promoting AMPAR insertion. For example, since GluN2B-containing NMDARs 
and SynGAP were demonstrated to be required for the proper establishment of homeostatic 
plasticity (Wang, Held et al. 2011; Wang, Held et al. 2013) we can hypothesize that NMDAR-
dependent regulation of SynGAP may become essential in FFI neurons for supporting synaptic 
scaling. 
On the other hand, PrP exerts an inhibitory function on NMDARs (Khosravani, Zhang et al. 2008), 
and a loss of physical interaction of the mutant protein may result in a reduced control of NMDAR 
activity. In view of this, it will be interesting to verify whether FFI neurons are more susceptible to 
NMDA toxicity. 
In summary, findings from this work confirm that PrP exerts a regulatory function on glutamate 
receptors homeostasis, and indicate that the aberrant interactions of mutant PrP with these 
proteins is responsible for structural and functional alterations of the postsynaptic compartment 
which affect excitatory neurotransmission and sensitizes neurons to excitotoxicity. In addition, our 
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findings may shed a light on the unsolved issue of phenotypic heterogeneity of prion diseases. 
Phenotypic heterogeneity is explained by postulating that different mutations assume specific 
conformations that are selectively toxic to different neuronal populations. However, the 
underlying mechanisms are unclear. Here, we provide evidence that distinct PrP mutations 
interact differently with glutamate receptors, altering their localization and function in different 
ways.  Based on our results, we propose that the differential interaction with specific glutamate 
receptors subunits, and most likely with other proteins which are differentially expressed across 
neuronal subpopulations, may be a determinant of phenotypic variability of prion diseases. Of 
course, however, the site-specific outcome of the interactions with synaptic proteins cannot be 
addressed by using a single in vitro model such as hippocampal neuronal cultures. For this reason, 
it will be essential to confirm our results in vivo, by focusing on the brain regions specifically 
affected in the different diseases.  
Given the broad, pleiotropic function of PrP, glutamate receptors homeostasis is likely to be only 
one of the many aspects of synaptic physiology that are affected in prion diseases. For example, 
we only focused on the postsynaptic compartment, but a role of PrP in regulating presynaptic 
neurotransmission has also been described (Senatore, Restelli et al. 2013; Robinson, Nugent et al. 
2014), and indications arguing for the presence of presynaptic defects were obtained in our 
experiments as well. 
These considerations underscore the need for elucidating all the possible mechanisms of synaptic 
pathology in prion diseases. As already mentioned, synapses are a very appealing target for 
therapy, not only because synaptic dysfunctions are the earliest pathological events, but also 
because, due to their intrinsic plasticity, synaptic alterations can be reversed. Ideally, the 
identification of a panel of specific synaptic dysfunctions for each disease may help to optimize 
therapeutic intervention for these multifaceted, untreatable disorders. 
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